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Abstract
Medication complexity and nonadherence are significant risk factors for avoidable
hospitalizations and health care spending for older adults in the United States. However,
limited empirical research has investigated pharmacist-run telephonic medication
management programs as a potential solution to the problem of reducing medication
complexity while improving medication adherence. This quantitative study employed the
behavioral change model to analyze archival data from a sample of 1,148 participants,
examining the relationship of a pharmacist-run telephonic consulting program on
medication adherence and medication complexity for one pharmacy benefit management
firm’s Medicare Part D recipients. The primary research questions investigated the
relationship of medication therapy management programs to medication adherence and
complexity. Data were assessed using correlation and regression analysis to determine
the association between receiving pharmacist counseling, medication adherence, and
medication complexity, and to assess the strength of any relationships identified. No
linear relationship was found between pharmacists’ counseling, medication complexity,
and medication adherence. However, the study found a weak correlation between
medication complexity and comorbidities, and between medication complexity and
medication adherence. This study promotes positive social change by identifying
information that can be used to reduce pharmaceutical industry liability by improving
proper management of medications, by reducing the burden of comorbidities related to
poor management of chronic disease, and streamlining health services and improving
their outcom
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Chapter 1: Introduction to the Study
Managing chronic diseases is often challenging for older adults who are aged 65
years and older. Multiple comorbidities, numerous medications, multiple health care
providers, and other factors contribute to medication nonadherence and self-management
issues for all individuals, but they have an additional impact on older adults
(MacLaughlin et al., 2005; NEHI, 2009; Smith, Catellier, Conlisk, & Upchurch, 2006).
Medication nonadherence is responsible for $100 billion in avoidable hospitalizations and
$290 billion per year in avoidable health care spending in the United States (NEHI, 2009;
Osterberg & Blaschke, 2005). Managing a chronic disease such as Type 2 Diabetes
Mellitus (T2DM) in older adults is especially challenging because of the complex
medication regimens and the existance of comorbitities (ADA, 2013). For T2DM
patients, reaching their clinical outcomes and goals is key to effective disease
management (ADA, 2013). This study investigated methods to improve medication
adherence for older adults with T2DM.
This study examined a U.S. pharmacy benefit management (PBM) company’s
medication therapy management (MTM) system and its impact on medication adherance.
In this system, pharmacists use telephone consulting in order to decrease medication
complexity and nonadherence to prescribed medications. While these management
practices are designed to benefit the individual patient, this strategy has the potential to
create positive, systemic changes for society. Increasing the proper management of
medications will positively impact the pharmaceutical industry by reducing liability,
improve public health by reducing the burden of comorbidities related to poor

2
management of chronic disease, and streamline health services to imrpove their outcome
(Lawrence, Qu, & Briskin, 2012; NEHI, 2009; Viswanathan et al., 2012).
Chapter 1 introduces the study topic and provides background information on
T2DM, medication nonadherence, PBM companies, and MTM pharmacist counseling
program. After presenting the problem statement, purpose and research questions, I will
briefly summarize stages of change theory and how this theory applies to medication
nonadherence. The chapter continues with the nature of the study, definitions, and a
discussion of the study’s assumptions, limitations, scope, and delimitations. The chapter
concludes with a discussion of the study’s significance and a chapter summary.
Background
Self-management of T2DM in older adults is challenging because of complex
medication regimens and the coexistance of comorbidities such as hypertension and
hyperlipidemia (ADA, 2013; Inzucchi et al., 2012). Successful management of treatment
depends not only on achieving proper glycemic control but on achieving treatment
balance between comobidities and quality of life (Pratley & Gilbert, 2012). The
prevalence of T2DM increases with increased life expectancy for older adults (Inzucchi
et al., 2012; Pratley & Gilbert, 2012). The Centers for Disease Control and Prevention
(CDC) estimated that in 2010, 390,000 older adults in the United States were newly
diagnosed with T2DM (CDC, 2011). Despite the high consumption of prescription
medications by older adults, it is not age itself but the age-related comorbidities that have
a high risk of polypharmacy (multiple medication use). Polypharmacy correlates with
increased adverse events, medication nonadherence, health care costs, hospitalization,
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and mortality (Budnitz, Lovegrove, Shehab, & Richards, 2011; Mansur, Weiss, &
Beloosesky, 2012). For older adults with T2DM, diabetes treatment is often intensive
and complex, creating challenges with medication adherence.
Pharmacy Benefit Management Companies
Pharmacy benefit management companies are specialized firms that manage the
prescription drug programs for most health plans (Lawrence et al., 2012). These
companies provide cost-effective drug-related administrative services and improving
medication adherence, resulting in positive patient outcomes. Pharmacy benefit
management companies promote medication adherence and improve health outcomes by
employing disease management (DM) programs that primarily focus on chronic
conditions such as diabetes, hypertension, arthritis, hyperlipidemia, and heart failure. In
PBMs, pharmacists may be at the leading edge for DM programs (Lawrence et al., 2012);
these pharmacists attempt to work proactively to educate patients on chronic conditions
and monitor programs designed to increase medication adherence.
Medication Complexity
There is a limited body of literature on PBMs’ use of MRCI scores on medication
nonadherence. Medication variables such as the number of medications, dosing
frequency, instructions, and prescribed dosage forms can all negatively affect adherence
(George, Phun, Bailey, Kong, & Stewart, 2004). These are measured in part by the
Medication Regimen Complexity Index (MRCI), which provides a numeric value that
reflects medication variables (formulation, dosing frequency, and special instructions)
and patient-level variables (disease specific medication, other prescribed medication and
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over-the-counter herbals or supplements; George et al., 2004). A review of the extant
research, detailed more thoroughly in Chapter 2, suggested that certain chronic disease
medication regimens are more complex than others are. In addition, medication
complexity has been positively correlated with medication nonadherence (Choudhry et
al., 2011; Libbey et al., 2013; Moore, Shartle, Faudskar, Matlin, & Brennan, 2013;
Pollack et al., 2010).
Medication Adherence
Medication adherence is a complex behavior that depends on self-efficacy to
perform the behavior, confidence in one’s medical providers, and a belief that the
medication treatment will work (DiMatteo, Haskard, & Williams, 2007). Medication
misuse and nonadherence result in the deterioration of a patient’s chronic condition and
increased hospitalizations and medical costs (Ho et al., 2006; Hughes, 2004; Mahoney,
Ansell, Fleming, & Butterworth, 2008). Interventions that include simplyfing drug
regimens, increasing patient education, and pharmaceutical counseling increases
medication adherence (Rodriguez de Bittner & Zaghab, 2011; Viswanathan, 2012).
Increasing medication adherence is complex, and may require more than one solution to
be successful.
At the time of this study, pharmacy benefit management companies in the United
States used two methods to measure medication adherence using pharmacy claims data:
medication possession ratio (MPR) and proportion of days covered (PDC). Both MPR
and PDC allow PBM pharmacists to monitor a patient’s adherence and to intervene when
deemed appropriate to ensure appropriate treatment (Brennan et al., 2012). In this study,
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I used MCRI scores to help identify medication complexity and MPR ratios to measure
adherence in a cohort of patients receiving medications in the treatment of T2DM.
Medication Therapy Management Programs
The Medicare Prescription Drug, Improvement and Modernization Act of 2003
(MMA 2003) was a U.S. Congressional health care reform bill that focused on preventive
medicine for chronic diseases to develop a mechanism to improve the quality of
medication management (Neuman & Cubanski, 2009). The centerpiece of this reform
bill offered Medicare beneficiaries outpatient prescription drug benefits (Meyer &
Cantwell, 2004; 108th Congress, 2003). To ensure drug safety and appropriateness for
the targeted beneficiaries, MMA 2003 required that all Medicare plan sponsors establish
and implement a medication therapy management (MTM) program.
Medication therapy management is a part of the family of DM programs and is a
distinct set of services designed to optimize therapeutic outcomes for the Medicare Part D
recipients (Schommer, Doucette, Johnson, & Planas, 2012). MTM programs are distinct
from other DM programs because of they incorporate analysis of a patient’s total
medication experience, not just the single chronic condition (Pellegrino, Martin, Tilton,
& Touchette, 2009). While many MTM programs deliver through face-to-face
consultations, several studies have shown that this delivery system is not always optimal
for the patient and the community pharmacist (Dolor, Masica, Touchette, Smith, &
Schumock, 2012; Schommer et al., 2012). Feifer, Greenberg, Rosenberg-Brandl, and
Franzblau-Isaac (2010) found that some patients are not always satisfied with
consultations that take place at the point of service. Because of this lack of satisfaction,
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telephone consultations have been proposed as a viable alternative to deal with this
dissatisfaction (Moczygemba et al., 2008; Ward & Xu, 2011; Wu et al., 2006).
Pharmacy benefit management companies are well-equipped to offer full clinical
pharmacist services, including MTM programs via telephone, to all Medicare health
maintenance organizations and other private insurance companies (plan sponsors) that
provide Medicare covered benefits (Neuman & Cubanski, 2009). The availability of
complete patient medication profiles via electronic data claims enables PBM MTM
pharmacists to remotely identify individuals who have the propensity to be medication
nonadherent. Telephone MTM services are an option to deliver patient-specific care for
health care plans offering MTM services to Medicare recipients. Pharmacists’ direct
patient care interventions have been shown to improve health care outcomes (Rodriguez
de Bittner & Zaghab, 2011; Schnipper et al., 2006; Moczygemba, Barner, Gabrillo, &
Godley, 2008). However, this study’s review of the literature indicated a gap in the
research investigating PBM MTM pharmacist counseling on medication complexity and
improved adherence.
Problem Statement
As the U.S. population ages, more people are being diagnosed with Type 2
Diabetes Mellitus (ADA, 2013). T2DM is a complex and lifelong chronic disease that
requires multiple medications, effective self-management, and medication adherence to
achieve therapeutic success (ADA, 2013). Many older adults with T2DM have existing
comorbidities such as hypertension, hyperlipidemia, and coronary heart disease, which
complicates treatment regimens and increases nonadherence (ADA, 2013). Older
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patients with T2DM who are medication nonadherent are at greater risk for
hospitalizations, emergency department visits, and all-cause mortality (Ho et al., 2006;
Lau & Nau, 2004; Yang et al., 2009). Complex medication regimens also have
documented negative effects on medication adherence and therepeutic outcomes
(Choudhry et al., 2011; Libby et al., 2013; Pollack, Chastek, Williams, & Moran, 2010).
Medication complexity and nonadherence have the propensity to undermine effective
treatments in complex chronic diseases such as T2DM.
There is a gap in the literature on the effectiveness of PBM telephonic systems
that pharmacists use to engage patients; however, several previous studies suggest that
this is an important area for research. Several studies have suggested that lack of patient
engagement in their health care is affected by embarrassment, inadequate reading
comprehension, and poor communications skills, posing a challenge to dispensing
pharmacists at the store level (Kirsh, Jungeblut, Jenkins, & Kolstad, 2003; von Wagner,
Steptoe, Wolf, & Wardle, 2009). Inadequate patient engagement has been correlated
with a decrease in self-management, affecting decisions in self-care (Mosen et al., 2007).
Counseling older adult patients in an environment without barriers can increase patient
engagement and medication adherence (Schnipper, et al., 2006; Tkacz, Metzger, &
Pruchnicki, 2008). Other researchers have evaluated hospital-based pharmacists using
telephone calls for consultation and was deemed successful as a communication medium
for increasing patient involvement with their treatment (DeWalt et al., 2006; Nazareth et
al., 2001; Wu et al., 2006). This study was designed to address this research gap.
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Medication therapy management programs in the United States are designed to be
distinct from medication-dispensing services and other DM programs. While studies
have been completed using community pharmacy-based DM programs on patient
medication adherence (Chawla, 2012; Fox, Ried, Klein, Myers, & Foli, 2009; Planas,
Crosby, Mitchell, & Farmer, 2009), there has been little research on the impact of MTM
pharmacists on medication complexity and medication adherence from a PBM system
using telephonic consulting. More research is needed to study the impact of MTM
programs on medication complexity and medication adherence in the older adult
population.
Purpose of the Study
The purpose of this quantitative study was to examine the effects of a pharmacist
PBM MTM telephonic consulting program on medication adherence and medication
complexity for a selected PBM’s Medicare Part D recipients. In this study, I used MRCI
scores as an indicator for medication complexity, and MPR ratios as an indicator for
medication adherence. I specifically examined an MTM telephonic program used by one
PBM for Medicare patients with T2DM (these indicators are further examined in Chapter
3). I sought to analyze whether MTM pharmacist counseling is a means to improving
medication adherence and compliance in an older adult population. Increased medication
adherence and compliance could help stem the high costs of unscheduled hospital and
emergency room visits while increasing positive health outcomes and decreasing health
care costs.
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Research Questions and Hypothesis
In this study, I evaluated the association of MTM pharmacist telephonic support
with medication complexity and nonadherence in a group of T2DM Medicare–D
beneficiaries enrolled in a specific PBM’s MTM program. The independent variable was
the PBM MTM pharmacist-counseling program, and the dependent variables were
medication complexity (as measured by a decrease in MRCI scores) and medication
adherence (as measured by an increase in MPR percentages). This investigation was
guided by two primary research questions.
Research Question 1: Is there an association between receiving medication
therapy management pharmacist telephonic support and medication complexity in
Medicare Part D beneficiaries having T2DM as measured by a change in MRCI scores
after controlling for age, gender, and comorbidities?
H01: There is not a statistically significant association between receiving
medication therapy management pharmacist telephonic support and medication
complexity in the Medicare Part D beneficiaries with T2DM as measured by a change in
MRCI scores after controlling for age, gender, and comorbidities.
HA1: There is a statistically significant association between receiving medication
therapy management pharmacist telephonic support and medication complexity in the
Medicare Part D beneficiaries with T2DM as measured by a change in MRCI scores after
controlling for age, gender, and comorbidities.
Research Question 2: Is there an association between medication therapy
management pharmacist telephonic support and medication adherence in Medicare Part D
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beneficiaries having T2DM as measured by a change in MPR percentages after
controlling for MRCI scores?
H02: There is not a statistically significant association between receiving
medication therapy management pharmacist telephonic support and medication
adherence in the Medicare Part D beneficiaries with T2DM as measured by a change in
MPR percentages after controlling for MRCI scores.
HA2: There is a statistically significant association between receiving medication
therapy management pharmacist telephonic support and medication adherence in the
Medicare Part D beneficiaries with T2DM as measured by a change in MPR percentages
after controlling for MRCI scores.
The Theoretical Framework
This study used the stages of change (SOC) theory for its theoretical framework.
SOC is a frequently used theory to explain behavior change (Prochaska & DiClemente,
1983). This model describes the stages of readiness, the decisional balances, and selfefficacy used by individuals in making a behavior change. Changing behavior such as
starting a new medication or taking medication on a daily basis for a chronic illness is
difficult for many individuals. Pharmacists can assist individuals who may require
information, education, guidance, or a combination in order to be medication adherent.
The five stages of SOC theory are instrumental in identifying a patient’s readiness for and
barriers to change; SOC has been applied extensively where change in behaviors has
been warranted (Prochaska, Redding, & Evers, 2008) and to explain medication
adherence behavior (Johnson et al., 2006a, 2006b; Willey et al., 2000).
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Pharmacists can lessen patient frustration and improve patient success by
understanding the patient’s stage of change, anticipating barriers to change, and
identifying patients who have relapsed (Prochaska, 2008). As pharmacists identify
patients in the different SOC stages, pharmacists can take specific actions by
recommending an appropriate intervention aimed at increasing adherence. For long-term
behavior change (e.g., chronic medication adherence), potential change strategies are
individualized and applied at every stage (Prochaska, 2008). As a patient’s skill and
confidence, increases in managing medication use, challenges, and health crises decline
(Hibbard, Mahoney, Stock, & Tusler, 2007).
Nature of the Study
In this quantitative study, I analyzed secondary data from a quasi-experimental
match-control study on older adults who had T2DM and associated comorbidities
(Moore, Shartle, Faudskar, Matlin & Brennan, 2013). The original study population
consisted of older adults (≥ 60 years) from a large employer group, with data collected
from October 1, 2007 through November 12, 2008. Through the present study, I sought
to evaluate the effectiveness of a pharmacist MTM program on medication adherence (as
measured by a change in MPR) and medication complexity (as measured by change in
MRCI scores) in one PBM’s employer-based Medicare population. The archival data
were obtained from a PBM, and multiple regression was used to test the hypotheses.

12
Definitions
Health literacy: “The degree to which individuals have the capacity to obtain,
process, and understand basic health information and services needed to make
appropriate health decisions” (IOM, 2004 p. 32).
Medication adherence: “The collaborative relationship between the patient (and
or caregiver) and his or her health care providers, leading to the patient's or caregiver’s
medication behavior coinciding with medical advice” (MacLaughlin et al., 2005 p. 232).
Medication complexity: The number of drugs, dosage frequency, administration
frequency, and the prescribed dosage forms that make up a patient’s medication regimen
(George et al., 2004).
Medication therapy management: “A distinct service or group of services that
optimizes therapeutic outcomes for individual patients that is independent of, but can
occur in conjunction with, the provision of a drug product” (APhA & NACD, 2005 p.3).
Patient-centered service: Health care providers who work one-on-one with
patients to understand their perspectives, needs, and concerns regarding their medications
(Oliveira, 2012).
Pharmacy benefit managers (PBM): “Third-party administrators responsible for
administrating clinically based services that enable them to manage drug spending for
their clients by improving price competition and increasing the cost-effectiveness of the
medications covered under client plans” (PCMA, 2003 p.iii).
Self-management education programs: “Patient education in preventive and
therapeutic health care activities, usually consisting of organized learning experiences
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designed to facilitate adoption of health-promoting behaviors” (Warsi, Wang, LaValley,
Avorn, & Solomon, 2004 p. 1641)
Targeted population: “Beneficiaries who have multiple disease states (typically
chronic conditions), use multiple Part D – covered medications, and are expected to
research (and exceed) the spending limit for the year” (Siecker, 2010 p.2).
Assumptions
Several assumptions informed this study. I assumed that all the pharmacists used
the same technique when reviewing the patients’ medication records and lab values and
assessing any initial primary drug therapy concerns. Differences in techniques used
could influence the patient’s decision to opt in to the program. Another assumption was
the data entered into the PBM's database were accurate. An additional assumption was
that all the individuals took their medications as reflected by the MPR scores from the
original data. Finally, I assumed that there was no pattern to any missing information.
Overt inaccuracies and a pattern of missing data could have biased the study results.
Scope and Delimitations
The scope of this study was dictated by the source of the archival data: one
PBM’s MTM pharmacist telephonic counseling service and related changes in
medication adherence, complexity, and patient engagement collected from older diabetic
patients from October 1, 2007 through November 12, 2008. For this study, the archival
data from the PBM were delimited to adults 60 years and older who had a diagnosis of
diabetes, were high-end prescription users, and have documentation in their patient
profiles showing the absence of recommended therapy in treating diabetes or the presence
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of drug therapy contraindicated in the treatment of diabetes. High-end prescription users
were identified as participants having 14 or more prescriptions within a 120-day period.
Exclusionary delimitations were those participants with dual coverage from Medicare and
Medicaid or without active prescriptions. This study was delimited to the examination of
MTM counseling service on medication adherence and medication complexity, and I did
not consider any association with health care costs, as Moore et al. (2013) covered their
study. I measured medication adherence by using MPR ratios, and MRCI scores to
measure medication complexity. The results of this study were intended to be
generalizable to adults 60 years and older with T2DM.
Limitations
The most important limitation in this study was the use of archival data from a
previous study of health care in a large PBM (Moore et al., 2013). Selection, quality,
included variables, and the method of data collection were not under my control, and
validation was not possible. The data set includes both intervention and control group.
The control group was formed from patients who declined to participate in the opt-in
MTM counseling service. Moore et al. (2013) used propensity scoring, matching the
control to the intervention group on several characteristics: age, gender, baseline days
supply of medications, baseline plan-paid pharmacy costs, physician visits, inpatient
visits, outpatient visits, and number of pharmacy derived conditions. Another limitation
was that individuals who chose to accept the invitation for the opt-in program might have
been inherently different in some immeasurable characteristics that could have
contributed to changes unrelated to pharmacist counseling. Lastly, the variable MRCI
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index was added to the data set and was not used by the pharmacists initially in the
evaluation of patient profiles.
Significance
Medication complexity and medication nonadherence have been implicated in
undermining effective chronic disease management. This, in turn, leads to poor
medication management and increases in health service users. Medication nonadherence
has been implicated as a major contributor to health care costs in the United States. Costs
due to medication nonadherence and the ensuing morbidity and mortality are primarily
borne by insurers, self-insured employers, and government agencies (Shrank, Porter, Jain,
& Choudhry, 2009). Pharmacy benefit management MTM telephonic programs provide
a unique opportunity to promote health by assisting patients to receive the appropriate
medication and to adhere to their medication regimens.
Pollack et al. (2010) demonstrated that as the regimen complexity increases,
medication adherence decreases, adding to disease burden in patients with T2DM.
Identifying medication complexity was designed to provide PBM MTM pharmacists a
more efficient approach to identifying high-risk patients. As a result, targeted
interventions could improve adherence and achieve optimum outcomes in diabetes
management, potentially reducing morbidity and mortality. Using medication
complexity as an indicator to identify medication nonadherence may be a useful strategy
for PBMs to reduce long-term costs and decrease downstream costs to payers. Pharmacy
benefit management companies have a key opportunity to improve patient health care
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directly as many patients are under, over, or inappropriately prescribed medications for
chronic conditions, which may lead to nonadherence.
Summary
For older adults, barriers such as treatment regimen factors (treatment complexity,
side effects, and dosing schedule) are more difficult to traverse than other factors such as
disease factors (symptom prominence and disease response), or environmental factors
(lack of family and social support), adding to medication nonadherence (Ingersol &
Cohen, 2008). Medication nonadherence could contribute to adverse events and reduce
the patient's self-management of their chronic medical condition.
Medication therapy management programs, a product of MMA 2003, are
designed to be distinct from other chronic disease programs and could be delivered faceto-face or via the telephone. Pharmacy benefit management companies are in an
excellent position to delivers MTM programs, as these companies have the tools
necessary to deliver prescription benefits while controlling prescription drug costs.
Medication therapy management programs, part of the DM programs, is but one of the
tools used by PBMs to control medication utilization and decrease health care costs.
Medication therapy management programs use a comprehensive patient-centered
approach in order to increase patient education on prescription medications, improve
treatment regimen factors, increasing medication adherence and reduce adverse events.
This chapter contained an overview of the research objectives, theories, and detail
of the specific research questions for this study. The aim of this study was to evaluate
pharmacists run MTM telephonic services on medication nonadherence and patient
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engagement in the Medicare Part D beneficiaries. Descriptions of the nature and purpose
of the study, study design, scope, limitations, and significance of the study were
provided.
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Chapter 2: Literature Review
Introduction
The purpose of this study was to assess a specific type of pharmacy benefits
management’s (PBM) disease management (DM) program service known as medication
therapy management (MTM). The MTM pharmacist counseling program examined in
this study was part of a PBM telephonic system for providing MTM services to Medicare
recipients. Pharmacy benefit management MTM pharmacist counseling is based on
increasing patient engagement and medication adherence to optimize therapeutic
outcomes. The stages of change (SOC) model was used to guide the overall research
framework.
This chapter discusses the current literature related MTM programs for older
adults, and is divided into eight sections. The first section investigates the stages of
change model of health behavior change and this theory’s application to MTM programs.
The second section examines literature pertinent to medication nonadherence. The third
section provides the underpinnings of MTM and community pharmacists as related to
increased patient engagement and medication adherence in targeted Medicare
beneficiaries. The fourth section focuses on key elements of treating chronic diseases
and its relationship to patient self-management and medication nonadherence. The fifth
section provides background on PBMs and pharmacists’ responsibilities for the various
clinical services. The sixth section briefly examines the health care of older adults and
provides the foundation of the Medicare Prescription Drug, Improvement, and
Modernization Act 2003. The seventh section provides a description of Medicare Part D
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(prescription drug benefit portion of MMA 2003) and the offerings of MTM services to
older adults. The eighth section examines MTM’s pertinence to medication adherence.
MTM use by PBM pharmacists is used to improve medication compliance and adherence
in older adults. This service originated from the Medicare Modernization Act of 2003
and the Medicare Part D prescription drug benefit that began on January 1, 2006. At the
time of this study, there was a limited body of peer-reviewed literature directly related to
MTM delivered by PBM pharmacists using telephonic consulting modes.
Literature Search Strategy
The literature search for this study was conducted using several multidisciplinary
databases available from Walden University. These databases included Academic Search
Complete/Premier, Cumulative Index to Nursing and Allied Health Literature
(CINAHL), Health & Medical Complete, Medline, ProQuest Central, PubMed, Sage
Premier, and Science Direct. The search primarily focused on articles published between
2004 and 2015; older articles were incorporated when deemed necessary. The search
keywords included chronic disease management, health literacy, Medicare Modernization
Act 2003, medication adherence, medication management, medication regimen
complexity index, medication therapy management, pharmacist, pharmacy benefit
management, self-efficacy, and telephone consulting. Multiple books, book chapters, and
relevant articles were also consulted with a specific focus on the SOC model.
Theoretical Framework
Changing medical behaviors such as starting a new medication or continuing to
take a maintenance medication can be daunting for many individuals. Medication
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nonadherence is a significant problem in the United States, especially for individuals with
chronic disorders requiring maintenance medications, such as heart failure, diabetes, and
HIV infection (ADA, 2013; Pratley & Gilbert, 2012). The reasons for intentional
medication nonadherence are numerous (Doggrell, 2010; Lehane & McCarthy, 2006;
Santhosh & Naveen, 2011). To improve medication adherence, the causes of
nonadherence must be understood and addressed using numerous multifactorial strategies
employed by health care professionals (Brown & Bussell, 2011). Ultimately, however,
the degree of adherence depends on a patient’s involvement in their own treatment
decisions.
This study is guided by the SOC model, which was originally developed to guide
research on how to quit smoking (Prochaska & DiClementi, 1983). The results from that
research revealed that behavior change is gradual, continuous, and occurred in stages
(Frankish, Lovato, & Poureslami, 2008; Prochaska & DeClemente, 1983). SOC theory
was used by researchers in public health, health promotion, and addiction studies because
the theory incorporated various processes and principles of change from leading
psychotherapy theory (Ficke & Farris, 2005; Prochaska, Redding, & Evers, 2008). When
applying SOC theory, a matched strategy to help the individual successfully use a new
behavior is identified according to their state of readiness.
The core constructs of SOC are precontemplation, contemplation, preparation,
action, maintenance, and termination (Prochaska, 2008). The theory’s central premise is
that individuals move through these stages as they initiate a new behavior, but that this
movement is not necessarily in a linear fashion, as individuals may need several attempts
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before behavior change is achieved (Prochaska et al., 2008). As individuals move
forward, individuals increase their self-efficacy in managing health decisions while
adopting positive health behaviors (Wiley et al., 2000).
Studies have suggested that individuals’ self-efficacy and decisional balance are
major influences on medication and health care utilization (Hibbard, Mahoney, Stock, &
Tusler, 2007; Johnson et al., 2006a; Johnson et al., 2006b). Self-efficacy comprises two
interrelated components: self-confidence, the ability to make and sustain changes; and
temptation, the impulse to relapse to a former stage (Johnson et al., 2006b). As the
individual builds self-efficacy, the individual's decisional balance has a positive shift
forward, propelling the individual to the next stage (Prochaska et al., 2008). Increasing
self-efficacy is important to maintaining a new behavior.
Behavior results from the interaction of three distinct factors (also known as
triadic factors), personal, behavior, and environment (Zimmerman, 1989). Self-efficacy
is part of a self-regulatory process related to how individuals use and combine the triadic
factors in an attempt to achieve a specific goal or behavior (Clark & Dodge, 1999).
Drawing from personal factors (information and beliefs), environmental (e.g., advice
from experts, role models) and one’s own behavior to make a decision to attempt a new
behavior (e.g., starting a new medication). If the trial of starting a new medication and
outcomes are successful, then another attempt is made. Individuals with greater selfefficacy, have a greater likelihood of repeating new behaviors than individuals with lower
self-efficacy (Clark & Dodge, 1999). Patients who maintain new behaviors are predicted
to see an increase in self-efficacy and reduced symptoms of the disease.
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A significant problem in effecting long-term change is that feelings of selfefficacy for some behaviors may diminish over time. This lack of self-efficacy may, in
turn, translate into negative changes of behavior, health status, and self-medication
management (Lorig & Holman, 2003), which are particularly prevalent in older adults
with chronic diseases (Johnson et al., 2006a; Lee, Grace, & Taylor, 2006). Treating
chronic diseases is limited by barriers that challenge older adults, reducing their selfefficacy and self-management, leading to nonadherent behavior (Lee, Grace, & Taylor,
2006). This study specifically investigated the effectiveness of pharmacists using
telephone or face-to-face services to assist patients in overcoming these barriers to
adherence.
In SOC theory’s precontemplation stage, an individual has no serious thought
about changing or initiating a new behavior. At this stage, an individual’s self-efficacy
and management skills are insufficient to initiate any behavior changes, rendering many
individuals frustrated, or discouraged (Berger & Grimley, 1997). This lack of selfefficacy also manifests in a lack of individuals’ awareness that they must be active
participants in their own health care (Hibbard, Mahoney, Stock, & Tusler, 2007). There
is a positive correlation between self-efficacy, management skills, and health care
engagement (Barlow, Wright, Sheasby, Turner & Hainsworth, 2001; Hibbard, Mahoney,
Stock, & Tusler, 2007).
In the contemplation stage, an individual gives serious thought to behavior
change. Individuals at this stage are usually medication nonadherent because they lack a
full understanding of their illness and the importance of their medication regimen, and
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may also be experiencing various types of barriers such as medication side effects, health
beliefs, finances, and medication complexity (Hibbard et al., 2007; Konkle-Parker, 2001).
Pharmacists may be instrumental moving the patient to the next stage by educating the
patient and removing the environmental barriers.
Preparation is the stage where individuals may have taken some steps already by
setting a date when to start their new medication. The individual’s self-efficacy and selfmanagement skills have improved but may not be sufficient to initiate a new behavior
(Fick & Farris, 2005). Any nonadherence problem would be most likely unintentional.
At this stage, pharmacists would encourage patients to associate taking their medication
with a daily event or events (Fick & Harris, 2005). Success at this stage is seen when
strategies are used to enhance commitment.
In the action stage, behavior change has taken place; however, individuals may
become nonadherent because of unresolved issues because of the medication, or they
may be experiencing other health problems (Fick & Harris, 2005). Individuals may lack
necessary social or community support needed to continue the new behavior. Follow-up
phone calls from a pharmacist to resolve any residue medications issues would assure the
success of the patient to move to the next stage (Konkle-Parker, 2001). Therefore, any
interventions in this stage should be geared toward supporting the new behavior.
In the maintenance and termination stage, the new behavior is now more than 6
months old and the individual has sufficient self-efficacy and management skills to
continue without fear of relapse (Prochaska et al., 2008). In this stage, patients are
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consistently adherent to their medications. Pharmacists need to be vigilant concerning
medication refill patterns and intervene as needed.
Konkle-Parker (2001) identified four different types of factors relating to
medication adherence:
1.

Medication related: medication side effects, regimen complexity, size and
taste of medication, dietary restriction, and duration of treatment regimen.

2.

Client related: health literacy level, health beliefs, health status, selfefficacy, and medication self-management.

3.

Provider related: relationship with physician, appointment frequency, and
communication skills with provider.

4.

Environmental: finances, transportation, and social support.

Pharmacists’ skills and interventions differ from one stage to another stage
depending upon the medication adherence factors (Ficke & Farris, 2005; Konkle-Parker,
2001). In the precontemplation stage, the pharmacist experiences more client and
provider related factors. In the contemplation, preparation, or action stage, the majority
of factors are medication related and some client- or provider-related factors (KonkleParker, 2001). Improving adherence is difficult, and the key for the pharmacist is to
move the individual one stage at a time for optimal success (Berger & Grimley, 1997;
Prochaska et al., 2008). Patient’s self-efficacy is improved when barriers to medication
adherence are lessened or removed.
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Medication Nonadherence
Medication adherence is one of the most intriguing and complex behaviors
demonstrated by patients (Hughes, 2004). Adherence is influenced by many social and
behavioral factors and is significant in influencing treatment outcomes (Brown & Bussell,
2011; Martin, Williams, Haskard, & DiMatteo, 2005). Poor adherence can render the
best treatment ineffective and continues to be a source of frustration to health care
professionals (Osterberg & Blaschke, 2005). Numerous efforts have been undertaken to
change the current findings of medication adherence
Medication nonadherence is a widely acknowledged and a pervasive problem that
involves all health care providers. A key to proper chronic disease management is being
adherent; yet nonadherence is observed in approximately 50% to 55% of older adults (≥
65 years) with chronic conditions (Doggrell, 2010; Lehane & McCarthy, 2006). This
population is exemplified by multiple chronic conditions, requiring complex medication
therapy and compounded by cognitive deficits, low health literacy, and inadequate oral
and written communication skills (Hughes, 2004; Ngoh, 2009). Poor disease
management may represent a greater risk for older adults due to multiple co-morbidities
and medication complexity.
Although the terms compliance and adherence are often interchangeable
compliance is associated with a more passive behavior where the individual agrees with
the physician’s advice but the individual is not fully engaged with treatment (Osterberg &
Blaschke, 2005). Being adherent, the individual is more actively engaged and in accord
with the physician’s recommendations (Doggrell, 2010; Vermeire et al., 2001; WHO,
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2003). Being adherent implies that there is cooperation and an established relationship
between the health care team and patient (collaborative care). Adherent behavior for
chronic diseases dictates self-management, an individual’s ability to take prescribed
medication appropriately, filling the prescribed medication, scheduling and attending
follow-up appointments, and having the self-efficacy to manage therapeutic behaviors
(Lorig & Holman, 2003;WHO, 2003). The focus of effective treatment adherence is
based on not only actions of health professionals but equally and more importantly by the
patients themselves. The more actively engaged patients are with their health care
provider and in their own health care, the more successful they are in their selfmanagement skills (Barlow et al., 2002; Hibbard & Cunningham, 2008). An adherent
patient is actively engaged, making daily decisions that affect their health and costs
(Hibbard & Greene, 2013). Ultimately, the level of adherence correlates with patient
engagement.
Medication complexity has been implicated in undermining effective chronic
disease management leading to poor medication management. Choudhry et al. (2011)
studied the relationship of therapeutic complexity on adherence and chronic disease (e.g.,
cardiovascular disease). This large retrospective cohort study used data prescription
claims from 1,827,395 patients. The mean age of the patient was 63 years. Therapeutic
complexity was defined as the total number of prescriptions, number of fills for
medications in different drug classes and for maintenance use, the number of physicians
who wrote the prescriptions, the total number of pharmacies, and number of different
pharmacies at which prescriptions were filled, the number of pharmacy visits, and the
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consolidation of these refills. The Choudhry et al. (2011) study results highlighted
complexity but also implicated variables such as multiple trips to pharmacies and
multiple physicians, which added to medication nonadherence.
Nonadherence is divided into intentional nonadherence (active and reasoned
decision process) and unintentional nonadherence (passive process) (Lehane &
McCarthy, 2006). Lehane and McCarthy (2006) identified unintentional medication
nonadherence with three key factors: (a) drug (medication scheduling, drug regimen,
drug side effects, and packaging); (b) patient (age and changing physiology, multiple
comorbidities, cognitive ability, health literacy and personal beliefs); and (c) healthsystem (patient-provider relationship, medication access, and social support). Intentional
nonadherence correlates to patients’ beliefs in accepting or disregarding professional
advice (Lehane & McCarthy, 2006). Unintentional and intentional factors are important
when considering medication complexity and the influences over maintenance
medication adherence.
From an economic standpoint, nonadherence to medication regimens can be
costly, as poorly controlled chronic conditions can require additional medical therapy,
increases in medical provider office visits, and nonscheduled hospitalizations resulting
from drug-related adverse effects (Ho et al., 2006; Hughes, 2004; Mahoney, Ansell,
Fleming, & Butterworth, 2008). The New England Healthcare Institute (2009) estimated
that $290 billion per year or 13% of total health care is due to intentional and/or
nonintentional medication nonadherence and $100 billion each year in excess
hospitalizations.
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Roebuck et al. (2011) compared medication adherence of four chronic disease
states (heart failure, hypertension, T2DM, and dyslipidemia) to health care costs in a
retrospective cohort study of 135,008 patients. The analysis included three measures of
health services use: inpatient hospital days, emergency department visits, and outpatient
physician visits. Across all conditions, there was a positive correlation between annual
inpatient hospital days and adherence, ranging from six fewer days for older adults with
heart failure to one fewer day for those with dyslipidemia. Finally, there was a reduction
in emergency visits and increase in physician visits in the more adherent patients.
Medication nonadherence is a complex problem involving many factors;
therefore, optimizing drug therapy outcomes needs a multipronged approach. Patient
health outcomes have shown improvement when patients are encouraged to take a more
active role in their health care (Coulter & Ellins, 2007). There is a positive correlation
between increased patient's self-efficacy with treatment and medication management and
use of services and cost (Evangelista & Shinnich, 2008; Osterberg & Blaschke, 2005).
Collaborative drug therapy management by various health care providers (pharmacists,
physicians, and other allied health professionals) in accordance with the patient became a
viable solution to maximize the patient’s health-related quality of life. The pharmacist
would share the responsibility for patient outcomes. To assume this level of
responsibility, the pharmacist’s role needs to shift from purely pharmaceutical dispensing
to more of a clinical role, where the pharmacist takes a more active role in drug
monitoring, patient education, and counseling (Patwardhan, Duncan, Murphy, & Pegus,
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2012). Pharmacists must now focus on patient and drug safety and develop relationships
with other health care providers.
Pharmaceutical Care
Pressure from policy makers, along with other factors, influenced the pharmacy
profession to undergo a number of substantial changes to increase the professions’
responsibility to reduce preventable drug-related morbidity and mortality (Carmichael et
al., 1997). During the 1990s both community and hospital pharmacists moved away from
a more traditional pharmaceutical dispensing role to a pharmaceutical care model as
drug-related problems (DRPs) were recognized as serious and urgent (Berenguer,
LaCasa, de la Matta, & Martin-Calero, 2004; Chewning, 1997; Helper & Strand, 1990).
This new model involved enhanced clinical skills of the pharmacist (drug therapy
monitoring, patient counseling and drug information services) and increased patient
engagement with their own care (Chewning, 1997). In the pharmaceutical care model,
pharmacists provided services such drug therapy medication management: identifying
problems, implementing solutions, monitoring outcomes. The desired outcomes were to
optimize the benefits of an individual’s pharmacotherapy and to improve the quality of
life.
At this same time, policy makers included pharmaceutical care in the 1990
Omnibus Budget Reconciliation Act (OBRA 1990) (Fulda & Hass, 1992). OBRA 1990
was enacted to assist in reducing the U.S. federal budget deficit. OBRA 1990 also was
instrumental in creating the Drug Utilization Review (DUR) boards (Fink, 2008). State
specific, DUR boards managed drug purchasing and formulary decisions for programs
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such as Medicaid, injured workers, and state employee benefits (Fink, 2008). OBRA
1990 was also responsible for requiring pharmacists to counsel all patients receiving
prescriptions. Pharmacists addressed items such as name of drug, intended use and
therapeutic outcomes, side effects, proper storage, possible drug to drug or drug to food
interactions, and any needed action in the case of a missed dose. Although originally
designed to assist Medicaid recipients with understanding their medications, this act was
quickly extended to all patients receiving prescriptions (Fink, 2008). OBRA 1990 was
the government’s comprehensive piece of legislation on medication process and drug and
patient safety.
Another approach to preventing drug-related problems involves having
pharmacists directly involved with monitoring drug treatments. In a community clinic
and hospital settings, pharmacists monitored the effectiveness of medications by
performing blood pressure, glucose, and cholesterol checks (Berenger et al., 2004).
Studies have shown improved patient outcomes with chronic conditions such as heart
disease, T2DM, hyperlipidemia when pharmacists increased patient engagement in their
own health care (Bluml, McKenney, & Cziraky, 2000; Cranor, Bunting, & Christensen,
2003; Fischer et al., 2000). Fischer et al. (2000), using a quasi-experimental design,
investigated if using pharmaceutical care services had beneficial effects on chronic
diseases. The priori consisted of health management organization (HMO) enrollees
(average age of 63 years) being treated for a chronic condition (asthma, COPD, or heart
disease). The intervention group received pharmaceutical care with their prescriptions,
and the control group did not receive this intervention. Pharmaceutical care consists of
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intensive counseling, education regarding medications, and regular monitoring. Fischer
et al. (2000) demonstrated that pharmaceutical care increased self-medication
management skills and awareness of medication side effects.
Community pharmacists were in an exceptional position to offer pharmaceutical
care services. Community pharmacists could review prescriptions for age
appropriateness, medical conditions, and concurrent medications. With their increased
availability, pharmacists were available to counsel patients on medication, and stress the
importance of medication adherence. Many times, it was the pharmacist who the patient
saw last prior to their medication being taken. Although many pharmacists at the retail
level openly embraced this new pharmaceutical care model (Berenguer et al., 2004)
researchers have shown that pharmacist-patient communication interaction at the
community level was less than optimal (Devraj & Gupchup, 2011; Flynn, Barker, Berger,
Lloyd, & Brackett, 2009; Swarstad, Bultman, & Mount, 2004). Patient education is a
vital intervention for older adults to be medication adherent.
Given the importance of providing clinical support to patients receiving
medication, and that this may not be happening at the retail setting, telephonic
communication could be a viable alternative venue for the pharmacist and the patient.
Older adults are especially vulnerable to medication nonadherence when faced with a
new diagnosis and medication treatment plan, and not being fully engaged in treatment
(NCPIE, 2007). Disease progression with complications and decreased quality of life has
been correlated with medication nonadherence (Hughes, 2004; Roebuck, Liberman,
Gemmill-Toyama, & Brennan, 2011; Sokol, McGuigan, Verbtugge, & Epstein, 2005;
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Yang et al., 2009). Telephone management by pharmacists was shown to be appropriate
for many chronic conditions (Car & Sheikh, 2003; Dolder & Dolder, 2010; Rickles,
Svarstad, Statz-Paynter, Taylor, & Kobak, 2005; Walker et al., 2011; Ward & Xu, 2011;
Wu et al., 2006). In patients receiving antidepressant treatment where nonadherence is
relatively high within the first 3 months, patient receiving telephonic support increased
medication adherence and improved clinical outcomes (Rickles et al., 2005).
Hospital discharge can be stressful especially for the older adult, as the patient
transitions to a new environment and then is expected to remember new medication
instructions. In a study by Dudas, Bookwalter, Kerr, and Pantilat (2001), follow-up
phone calls by pharmacists were shown to increase patient medication adherence.
Chronic conditions such as diabetes and cardiovascular disease have better outcomes
when treatment levels are at goal. Using telephonic interventions, pharmacists were
successful in managing their patients and getting them to their stated goal (Dolder &
Dolder, 2010; Walker et al., 2011). Phone-based settings may offer pharmacists and their
patients a wider variety of opportunities to deliver pharmaceutical care.
Chronic Disease Management
As chronic diseases became the dominant leading causes of death, the distinct
discipline and management of chronic diseases became a focus of public health (Davis,
Wagner, & Groves, 2000). The treatment and management of chronic disease often
changes over time according to fluctuations in patient symptoms and in the disease
process. The key to managing chronic disease is to improve both short- and long-term
health outcomes in the targeted population with the disease.
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Chronic disease management is no longer treating chronic diseases as separate
disease entities but rather is a team-based direct-patient care approach (Hibbard et al.,
2007; Lorig & Holman, 2003; Norris, Glasgow, Engelgau, O’Conner, & McCulloch,
2003). Patients with chronic conditions make daily decisions concerning selfmanagement (Lorig & Holman, 2003; Norris et al., 2003). For many, self-management is
a life-long task. Clinical management of chronic disease shifted from a focus of
primarily pharmacologic and technologic intervention, to include patient selfmanagement behaviors and education with increased clinician-patient interactions (Norris
et al., 2003). Pharmacists as members of a team-based approach for patient care saw
success for meeting patient needs and improving health care quality.
Self-management programs, in conjunction with provider patient care, empower
patients to solve personal health-related problems. The outcome is to increase quality of
life while living with chronic disease. As members of a health care team, pharmacists are
key to providing information on safe, effective, and optimal medication use (Carmichael
et al., 1997; Patwardhan, Duncan, Murphy, & Pegus, 2012; Rodriguez de Bittner &
Zaghab, 2011). In a collaborative care setting, the pharmacist and patient design health
care decisions together, with the pharmacist assisting the patient with problem-solving
skills to enhance self-efficacy and medication management (Bodenheimer, Lorig,
Holman, & Grumbach, 2002). This collaborative approach would help assure that the
patient needs would be met with improved health care quality. Using a pharmaceutical
care practice, the pharmacist validates the patient-defined problems (Bodenheimer et al.,
2002). Using multisite community pharmacies involving community pharmacists,
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Garrett and Bluml (2005) demonstrated that using consultations, clinical goal setting,
monitoring, and collaborative drug therapy had significant improvements in diabetes
management including improvement in reaching goals. Patients had increased
satisfaction with their diabetes care provided by their pharmacists.
An example of a chronic disease that warrants close adherence to prescribed
medications is T2DM. Type 2 Diabetes Mellitus is the seventh leading cause of death,
with prevalence of 25.8 million people in the United States (Qaseem, Humphrey, Sweet,
Starkey, & Shekelle, 2012). Type 2 Diabetes Mellitus can lead to long-term
complications such as microvascular, macrovascular, and cardiovascular disease.
Although medications have been shown to be efficacious in reducing short- and longterm effects of the disease, treatment goals are often not reached. Barriers leading to
treatment goal failure are numerous, but complex medication regimens and convenience
factors are prevalent for older adults (Nam, Chesla, Stotts, Kroon, & Jansen, 2011,
Osterberg & Blaschke, 2005). Provider-defined problems versus patient-defined
problems have also been implicated in medication nonadherence. For many patients it is
more important to avoid the adverse effects of hypoglycemia caused from oral diabetic
medications happening in the present than the possibility of kidney disease occurring in
the future (Bodenheimer et al., 2002).
It is important to understand nonadherence from patients’ point of view. It is
through personal communication that patients’ perceptions of treatment may radically
differ from that of the prescriber (Grant et al., 2011; Ramalho-de Oliveira, Shoemaker,
Ekstrand, & Alves, 2012). With diabetes, three main areas have been identified where
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patients’ perceptions differed from those of the treating clinician and ADA guidelines
(Grant et al., 2011; Ramalho-de Oliveira et al., 2012):
1.

Medication initiation was viewed as a negative event as it reflected personal
failure and an added burden.

2.

Medication intensification was viewed as a risk factor for diabetes-related
complication. Patients did not fully understand the disease process and
progression.

3.

Patients never voiced a concern regarding a delay in medication changes
and/or additions. ADA recommends regular assessments and changes as
needed (ADA, 2013). Most patients were focused only on the present and
not the future. Patients however, favored individualized medication
planning (Grant et al., 2011).

Type 2 Diabetes Mellitus treatment success depends upon medication adherence,
self-monitoring of blood glucose, nutritional and physical therapy, and frequent
laboratory and medical appointments (ADA, 2013). Pharmacy benefit management
pharmacists have access to a variety of patient medical and laboratory data. The
available data assists the pharmacist in looking for warning signs on poor treatment
adherence. In the case of diabetes, indicators of poor treatment adherence may include
blood glucose readings and blood pressure not at acceptable levels, erratic office visits,
weight gain, and dietary and medication nonadherence (Dang, 2013). Patients with
T2DM require a comprehensive treatment plan specially tailored to their needs, as
treatment will vary from patient to patient (ADA, 2013). Pharmacy benefit manager
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pharmacists are in a perfect position through telephone consulting to use communication
interventions to increase patient adherence and improve communication with a primary
care provider.
There is no ideal method to improve medication adherence. Today’s PBMs have
innovative programs that plan sponsors can use to help maintain the overall health of
company employees (Lawrence, Qu, & Briskin, 2012). Specific to this current study,
T2DM is a chronic condition that is a focus of MTM programs used to educate
customers. Currently, through personal communication with the patient, MTM
pharmacists play a key role by creating personalized therapy that takes into account the
patient’s specific attitudes and concerns about their medication regimen, as well as their
lifestyle factors (Lawrence et al., 2012.).
Pharmacy Benefit Managers
Pharmacy benefit managers are independent arms of many health plans whose
function is to reduce health plan prescription-drug costs while maintaining high quality
prescription-drug delivery and patient care (Lawrence et al., 2012). Pharmacy benefit
management companies manage the prescription drug plans for health insurance issuers
and plan sponsors (PCMA, 2003; Shrank et al., 2009). Pharmacy benefit managers create
provider networks of pharmacies and inter-related services for the health plans. While
some PBMs operate as independent entities selling PBM services to multiple types of
health plans, other PBMs are wholly owned by the health plan (PCMA, 2003). Whether
independent or owned, PBMs are one of the solutions to help curb with the rising
healthcare costs.

37
When Congress voted to expand the Medicare drug benefit to include outpatient
medication coverage, the overarching problem was how to pay, administer the benefits,
and use cost containment measures (Huskamp, Rosenthal, Frank, & Newhouse, 2000).
Congress received a number of different proposals with a common thread of allowing
PBMs as the administering agent to employ a PBM model for these Medicare programs
(Lawrence et al., 2012). Although the current PBMs were successful in reducing
pharmacy costs and increasing net savings with Medicaid programs in various states,
prescription drug costs are still on the rise (Lawrence et al., 2012).
Pharmacy benefit managers have not always been known for their clinical
services but have been judged largely on their cost-saving methods (Mullins & Wang,
2002; Shrank et al., 2009). However, factors such as new expensive drugs, greater
utilization of prescription drugs, the aging baby boom generation, and direct-to-consumer
marketing all gave rise to increasing prescription drug prices (Garis, Clark, Siracuse, &
Makoid, 2004). It was necessary for PBMs to design and integrate innovative programs
that would address these issues.
In order to increase health outcomes and still continue to curb health care
spending, PBMs needed to produce a more cost-effective pharmaceutical care system
(Shrank et al., 2009). Pharmacy benefit managers underwent a clinical process redesign,
integrating pharmaceutical care into clinical pharmacy services and medical services
across locations (Mullins & Wand, 2002; Shrank et al., 2007). Studies have shown that
multifactorial interventions that include better medication systems, education, and
communication were more successful in improving medication adherence (Barlow et al.,
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2002; Chodosh et al., 2005; Inzucchi et al., 2012; Kripalani, Yao, & Haynes, 2007;
Osterberg & Blaschke, 2005). With the use of electronic data, PBM MTM clinical
pharmacists via the telephone can provide not only the essential counseling and patient
education as mandated by the Centers for Medicare and Medicaid Services (CMS) but
can also perform screenings and assessments (Moczygemba et al., 2008; Shrank et al.,
2007). Essentially, electronic data have allowed pharmacists to assist patients with a
variety of nonadherence issues and bridge patient-physician communication gaps.
Pharmaceutical care services, later known as DM services, expanded PBM
pharmacists roles from mainly cost savings to covering safety, medication adherence,
educational, behavioral, and informational resources leading to increased quality of care
(Lawrence et al., 2012; PCMA, 2003). Clinical pharmacists proved to be well suited for
medication management due to their expertise on medication use and specialized training
on specific diseases (Sipkoff, 2007). Pharmacists running DM programs, including
MTM programs, were proving to be successful in the treatment of chronic diseases and
increasing therapeutic outcomes. By directly engaging the patient, PBM pharmacists
could reduce any perceived barriers and increase adherence and health outcomes
(Oladapo & Rascati, 2012; Shrank et al., 2009).
The Centers for Medicare and Medicaid Services allowed MTM services to be
delivered via face-to-face interventions, telephone consultations, and educational mail
campaigns. Feifer et al. (2010) found medication adherence increased when there was
telephone support by a clinical pharmacist soon after filling with a new prescription.
Pharmacists were able to identify and resolve medication-related problems, refer patients
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back to their medical provider for any new problems and fewer patients returned to the
emergency room compared to the non-phone follow-up group (Feifer et al., 2010).
Pharmacy benefit managers offering full services found that incorporating telephone
MTM services could provide patient specific care resulting in improved health outcomes
(Moczygemba et al., 2008). Medication therapy management services were effective in
increasing patients self-management skills and medication adherence.
Health Care in the United States Prior to MMA 2003
Despite the positive contributions by the pharmacy profession over the years,
there remained concerns about patient safety, drug therapy, and the quality of health care.
Studies howed that the costs of adverse drug events (ADEs) exceeded the initial cost of
medications (Ernst & Grizzle, 2001; Smith, 1993; Sullivan, Krelig, & Hazlet, 1990).
ADEs, inappropriate medications, and medication nonadherence were responsible for
increased rates of hospitalization (Brennan et al., 1991; Chutka, Takahashi, & Hoel,
2004; Fick, Nion, Beers, & Waller, 2008; Leape et al., 1991; Page & Ruscin, 2006). In a
large retrospective study of 11,500 patients with diabetes mellitus, nonadherence
accounted for 20% of the patients and was associated with elevated hemoglycolated
blood levels, blood pressure and lipid blood levels. Nonadherent patients had significant
risk for all-cause hospitalization and mortality (Ho et al., 2006a). Primary prevention is
crucial in treating and preventing future adverse events in T2DM.
Inappropriate drug prescribing to older adults continued to be a major concern as
it contributes to drug-related morbidity and mortality. Inappropriate medications are
those considered ineffective, lack efficacy, and have the potential to exceed the
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medication benefits placing older adults at great risk for adverse events. In a
retrospective small study of 390 patients, Page and Ruscin (2006) reported that 107
patients were prescribed an inappropriate drug, and 124 patients experienced ADEs. Fick
et al. (2008), in a large retrospective study of approximately 18,000 older adults,
identified 6,875 individuals (40%) with one inappropriate medication and 2,326 older
adults (13%) with 2 or more inappropriate medications. The Fick et al. (2008) findings
illustrated that inappropriate medication in the older adult can lead to ADEs, falls, and
injuries, leading to a poorer quality of life.
Nonadherence can be due to skipping, reducing the dose, or not filling the
prescription. In a 2-year time span prior to the enactment of MMA 2003, it was
estimated that approximately two million Medicare beneficiaries were medication nonadherent due to cost (Mojtabal & Olfson, 2003). Medication nonadherence was highest
among enrollees who had no or partial medication coverage. In a national survey of
approximately 17,600 Medicare beneficiaries prior to the enactment of the Medicare drug
benefit, 25% (4,400) of the enrollees reported medication nonadherence of one important
medication due to cost (Safran et al., 2005; Soumerai et al., 2006). Approximately 50%
(8,000) reported giving up basic necessities and groceries to be able to afford their
medications (Safran et al., 2005).
Older age is significant as an independent variable for adverse drug reactions
leading to hospital admissions. Older age is positively correlated to frailty, multiple
comorbid conditions, and polypharmacy, leading to hospitalizations second to ADEs
(Budnitz, Lovegrove, Shehab, & Richards, 2011). Gurwitz et al. (2003) examined the
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frequency of ADEs among 30,000 Medicare beneficiaries in an ambulatory setting.
Amongst 1,523 identifiable ADEs, 421 (28%) were considered preventable, and 578
(38%) were identified and classified as serious, life threatening, or fatal. In a national
surveillance of emergency department visits, older adults had the highest percentage of
ADEs and second highest of ADEs leading to hospitalizations (Budnitz et al., 2006).
Hospital admission was higher for individuals 75 years and older (11%) compared to
individuals 65 years and older (26%) (Doggrell, 2010). Drug-related problems and ADEs
are a prevalent problem seen in older adults with polypharmacy.
The overarching message from reviews of health care in the United States is that
there were large gaps between those individuals who were receiving care and the care
these individuals were receiving (McGlynn et al., 2003; Schuster, McGlynn, & Brook,
1998). Gaps in care were seen in all levels of care, from acute to preventative and
chronic. Overall, individuals only received 50% of the recommended interventions that
were involved in their care (McGlynn et al., 2003). For older adults, only 60% received
the needed care for chronic conditions (McGlynn et al., 2003). It was estimated prior to
2003, that only 64% of older adults received the needed preventative vaccines, 38%
received preventative cancer screenings and 25% did not have prescription drug coverage
(McGlynn, et al., 2003; Schuster, McGlynn, & Brook, 1998; Steinbrook, 2002). The
quality of medical care for the older adult falls short of acceptable levels for a variety of
conditions important to this vulnerable subpopulation.
There were also a lack of structured programs and outpatient medical providers to
provide assistance to older adults to help manage their medication regimens. This
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fragmented care led to increased chances for ADEs and poor adherence to treatment
plans (Smith, Catellier, Conlisk, & Upchurch, 2006). It was evident to policy makers that
newer approaches were needed to improve the quality of care and optimize health
outcomes of all adults (IOM, 2000). The enactment of the MMA was a national
milestone to improve health care and improve accessibility to prescription drug care to
older adults and individuals living with disabilities (Smith, Catellier, Conlisk, &
Upchurch, 2006).
The MMA of 2003
In 2002, the aggregate health care spending in the United States reached in alltime high of $1.6 trillion (Levit et al., 2004). Retail prescription drug sales accounted for
the largest increase in health care spending, reaching approximately $163 billion (Levit et
al., 2004). The current Medicare package did not include coverage for outpatient
prescription costs, leaving older adults to garner continuously the resources needed to
purchase medications and proper health care or do without some essentials (Mojtabel &
Olfson, 2003).
In a landslide move by policy makers, the MMA brought Medicare beneficiaries
health care and prescription benefits that would be consistent with those offered to
working-age Americans (Mojtabel & Olfson, 2003). Initiated in 2006, older adults and
individuals with disabilities could purchase a prescription drug plan (PDP) through a
benefit designated as Part D (optional drug benefit for Medicare beneficiaries who remain
in traditional Medicare Parts A or B) or as part of the Medicare Advantage program (MaPD) (i.e., managed care or private health plans) (Smith et al., 2006).
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The new law also required the plan sponsors offering PDPs or Ma-PD to offer
Medicare beneficiaries a new program called MTM. The CMS had expectations that
MTM services would improve drug therapy and medication adherence while reducing
prescription costs for older adults. Originally, CMS offered little guidance on the
parameters of the MTM programs and did not mandate the involvement of a pharmacist;
however, the CDC officially recognized the clinical experience of pharmacists as
providers and that they receive compensation for MTM services (Centers for Medicare
and Medicaid, 2005). Today, the vast majority of MTM programs use pharmacists to
provide this service as pharmacists are the ideal health care professional based on their
knowledge of drug therapy and accessibility to patients in the community (McGivney et
al., 2007; Shoemaker & Hassol, 2011).

Disease Management Therapy
With the adoption of MMA in 2003, a voluntary (also called opt-in) prescription
drug benefit program was offerred to all Medicare eligible recipients via the Medicare
Part D program. To help with the perverse problem of ADEs and poor medication
adherence in older adults at risk, MMA 2003 required that insurers provide an MTM
program (Meyer & Cantwell, 2004). At-risk older adults are noted for numerouse
chronic conditions, multiple medications, and physicians, leading to an increased risk for
adverse events. For effective health care and positive outcomes for the patient, health
information needs to be shared, and patient care must be a coordinated effort by all
providers and the patient (Chodosh et al., 2005). The Centers for Medicare and Medicaid
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Services required that MTM would be distinct from other currently offered programs
(Pellegrino, Martin, Tilton, & Touchette, 2009). Medicatuion therapy management
programs would be based on collaborative care and be patient centered.
Pharmacy practice at the retail level under OBRA 1990 required all pharmacists
to counsel patients about their prescriptions (Fink, 2005). The inherent problems with
OBRA 1990 were that the counseling represented a single event at the time of dispensing,
the patient’s history was not considered, and there was no follow-up by the pharmacist or
other providers to to ensure patient adherence (Pellegrino et al., 2009). Essentially,
patient counseling used to be a one-way conversation from pharmacist to patient, followup responsibility was placed upon the patient, and there was lack of patient engagement
in their medication management. Pharmacists now need to use patient counseling as a
tool to ensure that patients have the needed information to take a specific medication
properly (McGivney, 2007).
Disease management programs were adopted by many organizations in the 1990s
as patients with chronic diseases needed the coordinated efforts of various health care
providors where patient-self efficacy and engagement was significant (McGivney et al.,
2007). Many programs included physicians, nurses, nutritionists, and pharmacists. The
key objectives of DM were to focus on a single specific disease, provide patient
education, and increase patient self-efficacy and engagement in self care (McGivney et
al., 2007). These programs were instrumental in meeting a variety of patient drug and
disease specific needs. Pharmacist managed disease state programs included
anticoagulation, hypertension, lipid, asthma, diabetes, and others. These programs were
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robust in meeting the patients disease stated goals, and decreasing hospital admissions
and mortality (Chisholm-Burns et al., 2010; Chodosh et al., 2005). The success of these
programs were due to the two-way conversations between pharmacist and patient and
then follow-up to provider to create solutions to drug therapy problems. The main
drawback to DM programs was that the provided tools and education were limited to that
individual disease state.
Medication Therapy Management Services
The Centers for Medicare and Medicaid Services required three core outcomes to
their new program: (a) optimize patient therapeutic outcomes, (b) improve medication
adherence, and (c) detect and decrease ADEs and improper prescription medication use
(Pellegrino et al., 2009). With limited outcomes available on MTM services and to
encourage innovations and competition by pharmacy and other health care organizations,
the CDC did not clearly define all MTM activities and service provisions to achieve these
outcomes (Pellegrino et al., 2009). However, these services were to be developed as a
collaborative effort between pharmacists and physicians. More than 25 leaders
representing PBMs, health plans, health care organizations, and state and national
pharmacies constructed a consensus definition of MTM services (Curtiss, 2005;
Pellegrino et al., 2009).
Driven by the philosophy of pharmaceutical care, two major frameworks were
developed from the consensus definition. The frameworks were viewed as a
comprehensive drug-focused patient care service components for the pharmacist. Both
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MTM frameworks incorporate patient counseling, motivational interviewing, patient
assessment and education, documentation, and collaborative care (McGivney, 2007).
The American Pharmacist Association and the National Association of Chain
Drug Stores Foundation developed a framework representing the community
pharmacists. This platform focused on providing greater detail on the rationale and
procedures for the core outcomes as specified by the CMS (Pellegrino et al., 2009).
Operationally, this platform is for a face-to-face interaction; however, other routes
(home-visits or telephonic) are acceptable.
The Academy of Managed Care Pharmacy (AMCP) developed a framework
representing managed care and PBM pharmacies. This platform, focusing from an
insurers’ perspective, places greater detail on coordination of care, outcomes assessment,
patient identification, and collaborative care with other heath care providers.
Operationally, this platform is telephonic; however other routes (face-to-face or homevisits) are acceptable if supported by evidence (Pellegrino et al., 2009).
Medication therapy management service is distinct from the mandated counseling
that occurs as a result of OBRA 1990 and is more comprehensive than DM programs.
Specifically, MTM service has the following characteristics:
1.

It is patient-centered rather than product-centered. The pharmacist
considers each individual as unique, not only in how patients experience and
understand their medical conditions, but also in their personal values and
beliefs in regard to their care and treatment (Ramalho-de Oliveira,
Shoemaker, Ekstrand, & Alves, 2012). Patients’ medication adherence
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improved with an increased understanding of their disease, and the
perceived need for treatment and their medications (Maclaughlin et al.,
2005). A patient’s attitudes or concerns toward medication therapy will
vary from patient to patient and are often the basis of drug therapy
nonadherence. To resolve and prevent drug therapy problems, the
pharmacist needs to comprehend the patient’s medication experience. Only
after understanding the patient’s motivations and the root of their attitudes
and decisions can the pharmacist assist the patient with the process of
behavorial change, when warranted (Ramalho-de Oliveira et al., 2012).
This is a key issue when treatment is targeted toward prophylaxis or
asymptomatic treatment.
2.

Pharmacists focus on the patients total medication experience and not just
one from a particular disease state.

3.

Pharmacist-patient communication empowers the patient and increases
patient engagement in managing their own medications and health care
(Sieckler, 2010). Low health literacy, self-efficacy, and medication
complexity are factors that have been repeately recognized that impact
medication adherence. Having low health literacy may impede a patient’s
ability to correctly intrepret their clinician’s verbal and written instructions.
Other studies have found that low health literacy was associated with an
inability to read and comprehend prescription labels or correctly navigate
through complex medication regimens (Cameron et al., 2010; Hughes, 2004;
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MacLaughlin et al., 2005). Being medication adherent is more than just
taking medication, but is a complex process for the patient and healthcare
provider.
Service Delivery Mode
CMS did not specify regarding whether MTM should be provided face-to-face,
telephonically, mailed interventions, or combinations (Pellegrino et al., 2009). Face-toface MTM services may be performed at various different locations, as long as the
medication evaluation can be conducted in a private area (Shoemaker & Hassol, 2011).
Such MTM settings may include community pharmacy settings, ambulatory clinics,
institutional pharmacy practice, private pharmacy consulting services, or other areas
where there is a private area for the pharmacist-patient meeting (Shoemaker & Hassol,
2011). The Academy of Managed Care Pharmacy uses a combination of telephone and
mail, where interventions are mailed to both patients and providers. As MTM programs
have evolved, telephonic based services have increased in popularity as telephonic
services could be provided in the privacy of the patient’s home, provide patient-specific
care and be more accessible to Medicare beneficiaries with travel logistic problems
(Academy of Managed Care Pharmacy, 2008; Moczygemba, Barner, Gabrillo, & Godley,
2011; Shoemaker & Hassol, 2011). Medication Therapy Management telephonic
services were an efficient solution for government and private insurers to reach MTM
program eligible members.
While many community and clinic setting pharmacists found MTM rewarding,
surveys identified challenges to the successful provisions of these services. These
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barriers have included time and staff management logistics, reimbursement issues
(individual fee-for-service), patients’ lack of interest, and lack of access to patient records
(Dolor et al., 2012; Lounsbery, Green, Bennett, & Pedersen, 2009; McGivney et al.,
2007; Oladapo & Rascati, 2012). According to CMS MTM guidelines, MTM services
are considered as an administrative cost (Moczygemba et al., 2008). Health plans
providing telephonic MTM services incorporate this cost into the Medicare Part D plan
premium rather than having to bill for individual fee for service (Moczygemba et al.,
2008). By incorporating administrative costs within the MTM program itself,
government and health plans found a successful solution to reduce a barrier for MTM
implementation.
Patients’ Perceptions of Pharmacists as MTM Service Providers
The success of the MTM program was dependent upon two factors. The first
factor was the new role of the pharmacist, from the traditional dispensing model to a
clinician model. The second factor was the acceptance of the pharmacist in this new role
by the patients and will the patients have the same trust (Hong, Liu, Wang, Brown, &
White-Means, 2011; Moczgemba et al., 2010; Pellegrino et al., 2009). Patients have
always viewed the community pharmacist in the more traditional dispensing role rather
than in a clinical role (Law, Okamoto, & Brock, 2008).
Patients in general have found the pharmacist providing the MTM services as a
useful resource, and the information and type of service very important (Hong et al.,
2011; Moczgemba et al., 2010). Several researchers found a positive association in the
patients belief that MTM services can improve their communication and relationship with
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the pharmacist and improve medication adherence (Doucette, Witry, Alkhateeb, Farris, &
Urmie, 2007; Lauffenburger, Vu, Burkhart, Weinberger, & Roth, 2012; Law, Okamoto,
& Brock, 2008; Truong, Layson-Wolf, Rodriguez de Bittner, Owen, & Haupt, 2009).
Garcia et al. (2009) reported that patients did perceive some barriers to receiving MTM
services at the retail level. Barriers included location, parking, time of day/ week, and
fear that the recommendations may be contrary to their physicians plan of care (Garcia,
Snyder, McGrath, Smith, & McGivney, 2009). As more private insurance companies and
government turned to using a telephonic platform for MTM programs, many patient
challenges were resolved.
Measuring Adherence
Never before has the American population included so many older adults using
Medicare Part D drug benefits, increasing the importance of medications in the treatment
of chronic diseases (Kaiser Family Foundation, 2010; NEHI, 2009). Nonadherence
affects not only patients but also insurers, and employers as health care costs significantly
increase because of disease related complications. The Congressional Budget Office
(2010) predicted yearly expenditures on Medicare Part D medications would triple from
$59 billion in 2010 to an expected $177 billion in 2020.
One of the most challenging elements of quality improvement is measuring the
quality of care (Nau, 2009) and providing evidence whether prescription drugs provide
net economic value to those who pay for health care (Sokol, McGuigan, Verbrugge, &
Epstein, 2005). Adherence to medication is vital to quality health care and outcomes.
Adherence can be measured in several ways, for example, surveying patients, direct
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observation method, measuring drug blood levels, or using electronic medication
monitors (Osterberg & Blaschke, 2005). These direct methods can be labor intensive and
costly, and can limit the number sample subjects (Hudson, Rahme, Richard, & Pilote,
2007). For large populations of patients, health service researchers and pharmacy PBM’s
use pharmacy retrospective databases (refill claims) to describe medication adherence
and persistence in chronic diseases (Andrade, Kahler, Frech, & Chan, 2006; Choudhry et
al., 2009). None of the methods for measuring adherence are considered as a gold
standard (Hess, Raebel, Conner, & Malone, 2006). Two preferred methods of measuring
adherence and persistence using pharmacy drug refill claims data are (a) medication
possession ratio (MPR) and, (b) proportion of days covered (PDC) (Choudhry et al.,
2009; Karve et al., 2008, 2009; Nau, 2012). Karve et al. (2008, 2009) found that MPR
and PDC had the highest predictive validity for future hospitalizations and have formulas
in which better adherence corresponds to higher values.
The MPR and PDC are ratios that reflect the proportion of days during a defined
time period that a patient had possession of any of the drugs used to treat an illness. The
MPR ratio is calculated by the sum of days of medication supplied within a defined time
span divided by the number of days within that period (Nau, 2012). Although easy to
calculate, this method has come under scrutiny for its propensity to overestimate the true
rate of medication adherence as the numerator and denominator have been operationally
defined in different ways (Peterson et al., 2007).
The PDC is a newer method of calculating adherence. Proportion of days
covered, more operationally consistently defined, uses the number of fill dates and days’

52
supply for each fill of a prescription (Nau, 2009). Yet PDC is more than a simple
summation of the days’ supplies (Nau, 2012). In a comparative study, PDC provided a
more conservative estimate of adherence when patients were using dual therapy in a class
of drugs or switched to another drug from the same class of drugs (Martin et al., 2009).
This occurs frequently with antipsychotic and oral hypoglycemic medications.
Whether using MPR or PDC, the ratios are always between 0 and 1 and may be
represented by a percentage (ratio multiplied by 100). A MPR or PDC percentage of ≥
80% or ratio of ≥ 0.80 is the industry standard acceptance for adherence (Osterberg &
Blaschke, 2005). Performance measures such as MPR or PDC, when used to report
adherence rates of patients, the reported adherence rate reflects the percent of patients
who achieved the acceptable industry standard of adherence to the target class of drugs
(Nau, 2012).
Treatment adherence is key to better control of chronic conditions and is
associated with decreased emergency department visits, and hospitalization rates with an
overall decrease in morbidity and mortality (Roebuck, Liberman, Toyama, & Brennan,
2011; Yang et al., 2009). For patients with T2DM taking oral antidiabetic medications,
antihypertensives, and statin medications, all cause-hospitalization rates were increased
when adherence rates were < 80% (Ho et al., 2006; Yang et al., 2009). Lau and Nau
(2004) found that diabetic patients with adherence rates ≤ 80% were at a higher risk for
hospitalizations for the following year (odds ratio 2.53; 95% CI 1.38-4.64). In an
observational study, Sokol et al. (2005) evaluated the relationships among medication
adherence, medical utilization, and health care cost. The analysis covered four chronic
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disease states for which pharmacotherapy plays a key role in treating diabetes,
hypertension, hyperlipidemia, and heart failure. Patients who maintained ≥ 80%
medication adherence had the lowest rates for all cause hospitalization, which offset the
higher medication costs (Roebuck et al., 2011; Yang et al., 2009).
Medication Therapy Management Outcomes
It has always been the responsibility of the physician to ensure appropriate
treatment and medication adherence for their patients. With the rise of chronic diseases
and resulting complex treatments, pharmacists are in a unique position to fill an important
role in chronic care management (Patwardhan, Duncan, Murphy, & Pegus, 2012). Older
adults are at increased risk for ADEs and medication errors due to a greater prevalence of
chronic diseases, increased use of maintenance medications and greater dependency than
younger individuals are (Institute of Medicine, 2000). Proper treatment of chronic
diseases includes a variety of different modalities, including patient and life-style
management and targeted pharmacotherapy taken consistently on a regular basis
(Rodriguez de Bittner & Zaghab, 2011). Medication therapy management pharmacists
are an excellent resource for medication related questions thereby helping patients to
become more involved with their treatment decisions.
In a prospective cohort study, Brennan et al. (2012) used MTM service
recommendations in concordance with both mail order and retail. Pharmacists assisted
patients with medication adherence and the initiation of new medication orders. Patients
received their medications from a retail location, mail order, or both. The PBM used
information from both sources to develop interventions to improve medication adherence
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for the patient and encouraged the initiation of beneficial therapies. Patient visits and
calls were documented, and all recommendations were forwarded to the patient’s primary
provider. The intervention improved patients’ adherence rates and increased physicians
initiation rates (Brennan et al., 2012).
The important issue Brennan et al. (2012) brought to focus is that physicians may
erroneously assume that patients fill and take all prescribed medications. This problem
may further be compounded when physicians make inappropriate medication and dosage
changes leading to suboptimal health outcomes (Martin, Williams, Haskard, & DiMatteo,
2005). Thus, nonadherent patients may suffer from the lack of effective medications and
risk further complications from the disease. Specific to this study, I focused on
medication adherence.
Using a randomized controlled trial, Planas et al. (2009) evaluated a 9-month
community-based MTM program on quality of care in hypertensive, T2DM patients.
Clinical outcomes assessed were blood pressure and medication adherence. The
intervention group received MTM services on a monthly basis. The intervention
consisted of increasing patient engagement in diet, lifestyle modification, and medication
management skills. The control group received counseling on blood pressure at 3, 6, and
9 months. All visits were documented and shared with the patient’s primary physician.
Adherence with medications used in the treatment of hypertension was determined using
prescription claims data. At 9 months, the intervention group’s systolic blood pressure
(SBP) decreased by a mean of 17.32 mm Hg, and the control group SBP increased by
2.73 mm Hg. The mean adherence rate in the control group prior to the study was 79.5%
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and at 9 months was 78.8%. The mean adherence rate of the intervention group prior to
the study was 80.5% and increased to 87.5% at the end of the study. The intervention
group was effective at improving blood pressure and increasing medication adherence
(Planas, Crosby, Mitchell, & Farmer, 2009).
Planas et al. (2009) highlighted the importance of the MTM pharmacist as
medication experts. The MTM pharmacists were successful in providing patient-centered
care that resulted in medication adherence and better health outcomes. Planas et al.
demonstrated the effectiveness of pharmacists in evaluating patient response to therapy,
including safety and effectiveness. As the aging population and incidence of chronic
disease increases, utilization of pharmacists as medication experts is significant to
optimal healthcare delivery in the United States. In the current study, pharmacists as
medication experts were utilized in conjunction with patients and/or their caregivers to
promote the safe and effective use of medications and assist patients with medication
adherence. The ADA (2013) has documented the growing societal burden of T2DM.
Medication Therapy Management pharmacists are needed resources to aid patients with
self-management education and support services to enhance patient understanding and
appropriate use of medication.
Although the older adult represents only 13% of the population (USDHHS, 2010),
the prevalence for drug-related problems is disproportionately large compared with
younger individuals (Chutka, Takahashi, & Hoel, 2004). Drug-related problems are
multifactorial arising most often due to the number of medications, fragmented systems
of care, multiple co-morbidities, and the pharmacodynamic and pharmacokinetic changes
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seen in the older adult population (Fick et al., 2007). Older adults have more time that is
difficult recuperating from acute insults such as ADEs as compared to younger adults
(Hutchison, 2010). Multiple ADEs may lead to secondary fragility, increased disability
and death (Hutchison, 2010). Budnitz et al. (2006) reported that 32% of hospital
admissions were due to medications and drug interactions.
Moczygemba et al. (2011), in a quasi-experimental non-equivalent control group
study, assessed the impact of pharmacist-provided telephone MTM on medication, and
health-related problems (MHRPs), medication adherence, and Part D costs. The
intervention group received the MTM service at the start of the study. The assessment of
MHRPs in the control group was done using retrospective electronic chart review. MTM
services consisted of a comprehensive medication therapy review, medication action plan
and referrals. Action plans included MHRP recommendations regarding (a) medication
or dose changes, (b) drug safety and efficacy, (c) preventative care; (d) medication
education (individually tailored), and (e) cost/formulary interchange. All consultations
were documented with follow-up to the patient’s primary care providers. There were 4.8
MHRPs identified in the intervention group at baseline, and 2.5 unresolved MHRPs at the
6-month follow-up, a reduction of 48%. In the control group, 9.2 MHRPs were identified
at baseline, with 7.9 unresolved MHRPs at follow-up, a reduction of 14%. The
intervention and control groups had similar adherence rates at baseline, 67%, and 68%,
respectively. At the 6 month, follow-up adherence rates remained unchanged at 67% and
70%, respectively. In the intervention group, the mean Part D drug cost decreased by
$158.00 from baseline to 6-month follow-up and the control group increased by $118.00
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from baseline to 6-month follow-up. Moczygemba et al. (2011) noted that more than one
consultation and a longer follow-up period might have been necessary to determine
differences in medication adherence.
The Moczygemba et al. (2011) study is important in demonstrating the success of
a large private health plan using telephone and electronic medical records as an effective
method to deliver MTM services. Specific to this study, the focus was on MTM
pharmacists engaging patients to optimize therapeutic outcomes while promoting safe
and cost-effective medications. Using electronic medical records MTM pharmacists are
(a) able to evaluate patient medication adherence, and (b) assess whether medication use
by the patient contributed to a MHRP or if medication had failed to achieve the desired
outcome.
Moore et al. (2013), using a PBM medical claims database, researched the
relationship of MTM services on plan-paid health care costs, utilization of medical
services, overall days’ supply of targeted medications, and changes in MPR for 5
different chronic diseases (asthma, depression, diabetes, dyslipidemia, and hypertension).
This large retrospective study used a quasi-experimental pre- and post intervention
design. Moore et al. studied the effect of MTM services on plan-paid health care costs,
utilization of medical services, overall days of medication, and MPR. The program
intervention consisted of three consultations with clinical pharmacists over a time span of
one year to discuss drug therapy. The study found that the intervention group was
effective in reducing health care costs across all five chronic disease states; however,

58
only the conditions hypertension and dyslipidemia were statistically significant in
increasing medication adherence.
Although the problems of medical complexity specifically were not addressed by
the Moore et al. (2013) study, the results correlated with a previous study by Choudhry et
al. (2011). Choudhry et al. concluded that as the number of medications an individual
takes increases, the chance of medication nonadherence increases. T2DM is a complex,
chronic disease because of the coexistence of other comorbidities (hypertension,
dyslipidemia, heart failure, and/or depression). The treatment not only depends upon
treating diabetes but the successful treatment of the comorbidities. The significance to
the current study is the importance of the pharmacist to recognize disease and medication
complexity as it relates to the patient and medication adherence.
Measuring Medication Complexity
Polypharmacy is correlated with older adults and women; however, researchers
have found that age and gender do not contribute to medication complexity (Corsonello
et al., 2009; Mansur, Weiss, & Beloosesky, 2012). George et al. (2004) asserted that
when those who evaluate medications regimens for complexity should evaluate all the
different variables of the regimen, just not the medication count. Different variables
include number of medications, dosage frequency and administration, and the medication
dosage form (George et al., 2004).
Until recently there was no industry standard to quantify medication complexity.
To develop and validate the MRCI, information is used from medication charts,
prescriptions, and from electronic databases (George et al., 2004). The tool comprises
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three sections; (a) information of dosage forms, (b) dosing frequency, and (c) additional
directions. The complexity index is the summation of weighted scores from the three
sections. The weightings are based upon the degree of difficulty. In Section A, tablets
and capsules are the most convenient compared to other dosage forms (liquids, gargles,
sublingual sprays/ tabs, ointment, inhalation etc.). Tablets and capsules are assigned a
weight of 1; the other dosage forms are assigned a weight of 2 through 5. In Section B, a
tablet or capsule taken once a day is used as the baseline (Weighting 1). Additional
weighting of 0.5 was assigned for regimens that are administered at a fixed interval
(twice a day versus every 12 hours). Section C includes additional instructions per the
manufacturer or the physician (e.g., after or before meals, or at a specified time during
the day). George et al. (2004) tested the tool on a 134 different medication regimens from
patients who had moderate to severe, chronic obstructive pulmonary disease. This tool
was shown to have an inter-rater and test-retest correlation reliability of ≥ 0.9 (p < 0.001)
with respect to derived scores and expert panel rating medication regimen complexity
(George et al., 2004).
Libby et al. (2013) modified the MRCI to include a patient level MRCI subtype.
Many disease states include other comorbidities. Type 2 Diabetes Mellitus is often
complicated with hypertension and hyperlipidemia. The patient level MRCI subtype
includes disease-specific medications, other prescribed medications, and over-the-counter
(OTC) medications. In their cross-sectional retrospective study, Libby et al. (a)
compared patient-level MRCI scores across four chronic disease states (geriatric
depression, hypertension, HIV and diabetes; and (b) examined the importance of disease
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specific medication, other prescribed medications, and OTC medications in relation to the
total MRCI score. Geriatric depression had the highest total score, followed by HIV,
diabetes and hypertension Libby et al. concluded that dosing frequency and other
prescribed medications not related to the specific disease state heavily affected patient
level scores. In managing chronic disease states, it is vital to consider all the medications
that an individual takes and not just disease specific.
Conclusion
The studies reviewed in this section suggest that MTM services can lead to a
reduction in overall health care expenditures through increased medication optimization
and adherence and reduction in medication errors. Pharmacists today have an expanded
role as clinical providers in assuming a professional responsibility for patient's
medication therapy outcomes. The literature shows that pharmacist involvement in
patient care improves medication adherence and treatment outcomes.
Proper treatment of chronic disease is dependent upon not only a health care
system that recognizes the importance of the patient involvement in self-care; it also
requires an extremely engaged patient (Remmers et al., 2009). A fully engaged patient
has confidence and skills to promote personal health and to continue this behavior for the
long term (Remmers et al., 2009). Studies show that supporting, teaching selfmanagement, and self-efficacy skills for T2DM patients improve health with lower costs
of care (Dixon, Hibbard, & Tusler, 2009; Remmers et al., 2009). Not all patients are on
the same level of engagement, and as such, the pharmacists must tailor the patient
intervention to meet the needs of the patient’s level (Dixon et al., 2009).
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Chapter 3 provides an overview of the quantitative research study designed to
bridge the gaps in literature on patient engagement and telephonic pharmacist run MTM
service. Specifically, I will outline the techniques employed to explore the relationships
between medication complexity, patient engagement, and medication adherence. This
includes the study design, proposed research questions, a description of the sampling
frame, and power calculations based on available sample size. I will also discuss the
measures used to protect participants’ rights and privacy.
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Chapter 3: Research Method
Introduction
The purpose of this retrospective quantitative study was to examine the
relationship of a pharmacy benefit management (PBM) company’s medication therapy
management (MTM) pharmacist telephonic consulting program. This program was
designed to medication adherence and medication complexity for the selected PBM’s
Medicare Part D recipients. The study specifically analyzed the effectiveness of MTM
pharmacist counseling as a means to improving medication adherence and compliance in
an older adult population with type 2 Diabetes Mellitus (T2DM). The treatment of
T2DM requires lifestyle modifications, pharmacotherapy, and frequent blood glucose
monitoring. Achieving proper glycemic control requires education, motivation, and
continuous support from health care professionals (ADA, 2013). Medication therapy
management pharmacists are able to take an active role in patient education, provide
counseling in proper medication use, and address any barriers to adherence in the
treatment of T2DM.
This chapter details the research design and methods for this study, which
analyzed a dataset consisting of PBM pharmacy claims data from a large, national
employer prescription benefit plan in the United States. Within the research design and
rationale section, I review each of the research questions and provide a rationale for using
multiple regression and correlation to determine the relationship of receiving MTM
pharmacist counseling on medication adherence and on medication complexity. The
methodology section summarizes the study population, sample, and sampling procedures.

63
This includes the procedures for recruitment used by the PBM’s researchers from the
original study (Moore et al., 2013).
This discussion includes details on the predetermined sample size, my estimated
power for the proposed analysis, and an explanation of the methods used in the power
calculations. Next, I review the instrumentation used in the original study, including
methods to improve reliability and validity and the methods used in merging the data and
creating the variables used in this study. The data analysis section addresses the details
of data review and cleaning, and describes the analytic methods in detail. In the final two
sections, I discuss the threats to internal and external validity, including steps I took to
minimize them, ethical procedures taken to gain access to the data, and procedures used
to protect the data and participants.
Research Design and Rationale
This study used two primary research questions.
Research Question 1: Is there an association between receiving medication
therapy management pharmacist telephonic support and medication complexity in
Medicare Part D beneficiaries having T2DM as measured by a change in MRCI scores
after controlling for comorbidities?
H01: There is not a statistically significant association between receiving
medication therapy management pharmacist telephonic support and medication
complexity in the Medicare Part D beneficiaries with T2DM as measured by a change in
MRCI scores after controlling for age, gender, and comorbidities.
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HA1: There is a statistically significant association between receiving medication
therapy management pharmacist telephonic support and medication complexity in the
Medicare Part D beneficiaries with T2DM as measured by a change in MRCI scores after
controlling for age, gender, and comorbidities.
Research Question 2: Is there an association between receiving medication
therapy management pharmacist telephonic support and medication adherence in
Medicare Part D beneficiaries having T2DM as measured by a change in MPR
percentages after controlling for MRCI scores?
H02: There is not a statistically significant association between receiving
medication therapy management pharmacist telephonic support and medication
adherence in the Medicare Part D beneficiaries with T2DM as measured by a change in
MPR percentages after controlling for MRCI scores.
HA2: There is statistically significant association between receiving medication
therapy management pharmacist telephonic support and medication adherence in the
Medicare Part D beneficiaries with T2DM as measured by a change in MPR percentages
after controlling for MRCI scores.
The first research question addressed if receiving MTM counseling has a
relationship to medication complexity; the other, if receiving MTM counseling has a
relationship to medication adherence. The goal of both questions was to determine an
associated relationship between independent and dependent variables. To determine
these relationships, participants were followed over time after an intervention has been
imposed.
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The use of a cohort study design was appropriate for this study because there was
preexisting evidence to suggest an association between an intervention and outcome and
the interval between the intervention and development of the outcome was relatively
short to minimize loss to follow-up, in accordance with the suggestions of Carlson and
Morrison (2009) and Issel and Handler (2009). Because cohort designs allow for data
collection prior to the intervention, and due to the temporal nature of the design, cohort
designs may be able to assess relationships (Carlson & Morrison, 2009; Issel & Handler,
2009).
Cohort studies are increasingly used in research as they combine elements of
observation and experimental research methods, but have several distinct disadvantages.
One is loss of participants to follow-up and the costs of maintaining contact during the
evaluation follow-up (Carlson & Morrison, 2009; Issel & Handler, 2009). Loss due to
attrition may have adverse consequences for design validity and the statistical
conclusions (Carlson & Morrison, 2009; Issel & Handler, 2009). Another disadvantage
is that there may be alternative explanations for the study results. It is important,
therefore, to consider confounding factors when evaluating study results (Carlson &
Morrison, 2009; Issel & Handler, 2009).
This research study used secondary data from health care claim records at a single
PBM. There are several advantages to using secondary archival data. Doing so offers an
economic approach and access to a larger data pool, and it may establish observations
that may not have been present at the time of the original data collection (McKenzie,
Neiger, & Thackeray, 2009). The secondary analysis of archival data also provides
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researchers with increased opportunities to develop new knowledge (McKenzie, Neiger,
& Thackeray, 2009). Another advantage of using secondary data is that such data are
more readily available than primary data. In contrast, a major disadvantage is that there
is less control over data collection and data entry and one cannot determine firsthand the
reliability and validity of the data (Issel & Handler, 2009). Another disadvantage is that
secondary data may be several years old (Issel & Handler, 2009).
Methodology
Population
This secondary data analysis reused data from a study conducted by a PBM
company in 2013 (Moore et al., 2013). Moore et al. (2013) used data from 4,500 highrisk members of a large employer group to examine the effectiveness of MTM on therapy
adherence and clinical outcomes. All member participants in Moore et al.’s study had a
diagnosis of asthma, depression, T2DM, hypertension, and/or hyperlipidemia. The
current study used a subset of Moore et al.’s (2013) population, consisting of high-risk
plan members 65 years and older who were recorded as having T2DM. The PBM study
database used by Moore et al. provided eligibility information, pharmacy claims, and
medical claims for the T2DM subset (n = 1,157), who were identified using the ICD-9
code of 250.x.
Power analysis. Statistical power depends on three classes of parameters: (a) the
significance level (α), (b) the size of the sample used for the intervention, and (c) the
effect size (f 2), the expected differences in the means between the control and
interventional groups expressed in standard deviation units (Creswell, 2009).
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Conventional set values for these three factors are usually set as α = 0.05, power (1-β) =
0.80, and medium effect size (f 2) = 0.15. The power (1-β) of a study, typically presented
as high, medium, or low, denotes the beta error probability of falsely retaining an
incorrect null hypothesis.
I conducted a post hoc power analysis because this was a secondary analysis of an
already published study (Cohen, 1988; Faul, Erdfelder, Land, & Buchner, 2007). Post
hoc power analysis was obtained using G*Power 3.1.2 (Faul et al., 2007). In a post hoc
analysis, power is computed as a function of alpha, the population effect size, and the
sample size used in the study. For this post hoc analysis, I used a small effect size (f2 =
0.02, alpha = 0.05), and a sample size of 1,157. The post hoc analysis using multiple
regression revealed that a sample size of 1,157 with two predictors and four predictors
both achieved a power of 99%, a good threshold for power to avoid type II error (Faul et
al., 2007).
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Figure 1. A graph showing the post hoc analysis distribution.
Sampling and Sampling Procedures
The target population for the original study was comprised of high-risk plan
members, from a large nationally diverse managed care health (Moore et al., 2013). Plan
members were considered high-risk if they
•

were 18 years of age or older;

•

were heavy prescription users (14 or more claims in a 3-month period);
and

•

had a pharmacy profile that showed the absence of a recommended
treatment therapy or the presence of a conflicting treatment therapy in the
treatment of conditions such as asthma, T2DM, hypertension,
dyslipidemia, and/or depression.
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Pharmacy benefit management MTM pharmacists identified a total 13,092 highrisk plan members between October 1, 2007, and November 12, 2008 (Moore et al.,
2013). Plan members were excluded if they had dual coverage of Medicare and
Medicaid or lacked medical plan payments (n = 8,723). After completing three pharmacy
consultations with clinical pharmacists, 2,250 plan members enrolled in the program and
6,463 plan members declined. Plan members that declined during this period became
part of a control group (n = 2,250). The original study consisted of 4,500 plan members.
Propensity scoring was used to match the control group to the intervention group. The
T2DM subgroup consisted of 1,157 plan members, 546 were in the intervention group,
and 611 were in the control group.
Procedures for Data Collection
The collection of primary data using the high-risk plan members was performed
prior to this study (Moore et al., 2013), and PBM pharmacy personnel handled all data
entry. The PBMs pharmacy systems were responsible for quality assurance including
checking data entry for errors. The original data are stored and saved on a directory in
this PBM data environment. The data was not archived but saved as a data set.
I obtained the diabetes data set from this PBM after approval of my proposal by
Walden University Institutional Review Board (IRB). All data requested from this PBM
was required go through the mandatory Confidential Information Access Request (CIAR)
process, the formal proposal in writing outlining the need for proprietary study data.
After approval of my CIAR, I gained access to the data files from J. Moore, a member of
the enterprise analytics department of this PBM and author of the pilot study (Moore et
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al., 2013). Prior to releasing the electronic files to me, Moore de-identified the data,
removing all personal identifying markers (i.e., names, addresses, Social Security
numbers, and plan member identification numbers). The CIAR document approval is
located Appendix B.
Instrumentation and Operationalization of Constructs
Treatment complexity. All patients in the diabetes cohort were assigned a
complexity score based upon an algorithm developed by George et al. (2004). The
Medication Regimen Complexity Index (MRCI) is an instrument composed of 65-items
used to quantify complexity of medication regimens and has been used in adherence
studies (Libby et al., 2013; McDonald et al., 2013; Pollack et al., 2010). The MRCI was
found to be valid with an inter-rater and test-retest reliability of ≥ 0.9 (George et al.,
2004) and valid tool for quantifying the complexity of medication regimens (Libby et al.,
2013; McDonald et al., 2013; Pollack et al., 2010). The instrument consists of three
sections: (a) route of drug administration, (b) dosing frequency, and (c) additional
directions. Additional directions are recommendations by the manufacturer product
insert (Facts & Comparisons eAnswers, 2013) or physician, which a patient may need to
follow in adhering to a prescribed regimen (e.g., at a specific time). The sum of the three
sections contributes to the complexity index. This study used only those items in the
MRCI that were applicable to oral and topical prescription medications. The MRCI was
calculated from the drug database at baseline and then after the intervention. The
significance of using the MRCI score was that it could be a useful tool in facilitating
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MTM pharmacists in identifying patients who may have been at a higher risk medication
nonadherence.
Calculating MRCI score. The original index includes the summation of
weighted components of (a) dosage form, (b) dosing frequency, and (c) additional
administration instructions (see Appendix A). For a patient taking medications, the
minimum MRCI index score would be 1.5. This score represents a single tablet or
capsule taken once daily as needed; the number increases with the number of
medications.
Component A: Dosage form/route. Component A incorporates a weighting
scheme for dosage forms (tablet/capsule vs. spray vs. drop vs. ampoule), and route of
administration. Nasal sprays, oral or ophthalmic drops, and subcutaneous ampoules are
considered more complex than tablets or capsules and are given a heavier weight. The
MRCI developers provided weights for 32 different combinations. For this study, I only
used items in the MRCI that were applicable to oral medications and topical patches
pertinent to diabetes and associated comorbidities. Representative combinations are
presented in Table 1 (alignment of PBM data to MRCI components). To tabulate Section
A, a given form/route combination is counted only once within a regimen. For example
if a patient takes two capsules and two tablets, the subset score for Section A is 1.
However, if a patient takes two tablets and uses a nasal spray, then the patients' subset
score for A is 3.
Component B: Dosing frequency. George et al. (2004) included 23 weights
ranging from 0.5 for a once daily as needed up to 12.5 for medications that need to be
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taken or used every2 hrs. For this study, only dosing frequencies applicable to oral
maintenance medications was used (see Table 1). Dosing frequency is tabulated to
account for all medications. For example if the patient is taking two tablets and two
capsules and all four medications are taken once a day, the Component B subset would be
scored as 4. If a patient were taking two tablets each once a day and uses a nasal spray
on alternate days, the Component B subset score would be 4.
While it may be helpful to identify a given medication and possible dosing
frequency, this information does not provide specific dosing information for a specific
individual. Frequency is not in automatic property linked with a manufacturer's
identification number. For this study, drug dosing was calculated per the manufacturer’s
suggested dosing and days’ supply of medication.
Component C: Additional directions. George et al. (2004) provided for 10
additional directions a patient may need to follow for a patient to be fully medication
adherent (George et al., 2004). Special instructions were obtained from the patient
message code that was linked to the drug identification number. Table 1 Component C
represents examples and their assigned weights. A weight is given per each instruction
per medication. For example, if a patient needs to take two capsules needed before
breakfast and two tablets at bedtime, then Component C subset score is 4. The MRCI
score for this patient would be the sum of section A (1) + B (4) + C (4) = 9. The higher
the MRCI score of the medication regimen, the more complex the regimen becomes
(Libby et al., 2013). For this study, the MRCI score was calculated at baseline than after
the intervention.
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Table 1
Alignment of PBM Data to MRCI Components
MRCI component A:
form/route- weight

MRCI component B:
dosing frequency- weight

MRCI component C:
special instructions - weight

Tablet/capsule oral

1

Once a day

1

Liquids

oral

2

Twice a day

2

Sublingual

oral

2

Three times a day
Four times a day

3
4

On alternate days or less
frequently

2

Break or Crush tablet
or
Do not break or crush
Multiple units at one
time
Take at specific times
Take in relation to
food
Variable dose

1

Tapering or increasing
the dose.
Alternating the dose
Take as directed

2

1
1
1
1

2
2

Note. Adapted from George, J., Phun, Y., Bailey, M. J., Kong, D., & Stewart, K.(2004). Development
and validation of the medication regimen complexity index. The Annals of Pharmacotherapy, 38(24)13691376. doi:10.1345/aph.1D479
.

Treatment adherence. The MPR, a measure of adherence, was calculated for
each patient in the study for each oral medication that the patient used. Medication
possession ratios were calculated from claims data as the sum of days during the year
when the patient had the medication divided by the number of days in the year. The
MPRs for each oral medication were then weighted by the percentage of time. An
average composite score was computed for each patient. The value of the MPR ranges
from 0 to 1. Patients were considered adherent if they obtained MPR score was ≥ 0.8
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(80%) (Choudhry et al., 2009; Osterberg & Blaschke, 2005; Zhang et al., 2010).
Medication possession ratios for this study were calculated at baseline and then after the
intervention.
Study Variables and Covariates
Dependent Variable
The dependent variables were medication adherence and medication complexity.
The medication possession ratio measures medication adherence, and changes in this
ratio indicate whether individuals are more or less adherent to their medication regimens.
Increased adherence with medication regimens lessens adverse events. The Medication
Regimen Complexity Index (MRCI) measures medication complexity. Medication
Regimen Complexity Index is a composite number that represents the complexity of an
individual's medication regimen. Reducing the MRCI score represents a less complex
medication regimen. Simplifying medication regimens increases medication adherence.
Both the MRCI score and MPR ratios are measured before the intervention and then after
the intervention. Medication adherence and medication complexity, their source,
potential responses, and level of measurement are presented in Table 2.
Independent Variable
The MTM program is the intervention and the independent variable for this
research. Medication therapy management programs essentially are to resolve and
prevent drug therapy problems and increase medication adherence. The primary focus
was the changes in MRCI scores and MPR ratios. Medication therapy management
program source, potential response, and level of measurement are presented in Table 2.

75
Covariates
The covariate in this study included age, gender, and comorbidities. Studies
(Doggrell, 2010; Lehane & McCarthy, 2006) have shown that age itself not necessarily
influences medication nonadherence; however, poor disease management may represent a
greater risk for older adults due to multiple co-morbidities and multiple medication use,
leading to medication complexity. Polypharmacy correlates with increased ADEs,
medication nonadherence, health-care costs, hospitalization, and mortality (Budnitz et al.,
2011; Mansur et al., 2012).
Table 2
Study Variables
Variable
Type
Dependent

Level of
Measurement
Continuous

Potential
Response
percentage

Continuous
Nominal

Range from 3-60
Yes/No

Covariates

MRCI*
MTM** counseling
program
Age

Continuous

Age in years

Covariates

Gender

Nominal

Male/Female

Dependent
Independent

Variable Name
MPR±

Source of data
Calculated†
Calculated†
PBM claims
database
PBM claims
database
PBM claims
database

† See discussion of calculations in instrumentation and operationalization
±
Medication Possession Ratio, * Medication Regimen Complexity Index, **Medication Therapy
Management

Data Analysis Plan
This was a quantitative secondary analysis of a cohort study on MTM pharmacist
counseling program from a large PBM company on medication adherence and clinical
outcomes on high-risk individuals (Moore et al., 2013). The primary study identified the
target population from a national plan sponsor that covers employees, retirees, and
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dependents. Medication therapy management (MTM) pharmacists from the PBM
stratified the target population into two groups, intervention, and control.
Descriptive statistics using SPSS v.21 described the patient characteristics. Each
patient's age, number of medical conditions, number of medications and medication
complexity were described as the means. Medication adherence was labeled as a
percentage. I used a two-sided tail in all analysis and a p-value of less than or equal to
0.05 was considered statistically significant.
Analysis Plan for Research Question 1
I used correlation and multiple regression analysis to see if there was an
association between receiving MTM pharmacist counseling (independent variable) and
medication complexity (dependent variable) and to measure the strength of the
relationships between both variables while controlling for age, gender, and comorbidities.
The hypothesis was expressed as a p-value, the correlation coefficient r2 described the
strength of the relationship, and the regression line illustrated the relationship of the
variables. The coefficient correlation can fall anywhere between -1 to 1. The closer the
value of r2 is to 1, the stronger the linear correlation. A value of 0 denotes little or no
linear correlation. To test for the hypothesis, tstat = r/SEr, where SEr = √ 1- r2/n - 2
degrees of freedom. Squaring r derives a statistic called the coefficient of determination
(r2), which quantifies the proportion of the variance in the dependent variable
(medication complexity) explained by the independent variable (MTM pharmacist
counseling). The t-stat is converted to a p-value. The hypothesis would rejected if p <
0.05.
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Analysis Plan for Research Question 2
I used correlation and multiple regression analysis to see if there was an
association between receiving MTM pharmacist counseling (independent variable) and
medication adherence (dependent variable) and to measure the strength of the
relationships between the both variables while controlling for MRCI scores. The
hypothesis was expressed as a p-value, the correlation coefficient r2 described the
strength of the relationship, and the regression line illustrates the relationship of the
variables. The coefficient correlation can fall anywhere between -1 to 1. The closer the
value of r is to 1, the stronger the linear correlation. A value of 0 denotes little or no
linear correlation. To test for the hypothesis, tstat = r/SEr, where SEr= √ 1- r2/n - 2
degrees of freedom. Squaring r derives a statistic called the coefficient of determination
(r2), which quantifies the proportion of the variance in the dependent variable
(medication adherence) explained by the independent variable (MTM pharmacist
counseling). The t-stat is converted to a p-value. The hypothesis would be rejected if p <
0.05.
Correlation and multiple regression are appropriate tests when there are
continuous and a nominal variables, and to check if two variables are associated, without
necessarily inferring a cause-and-effect relationship (McDonald, 2009). Assumptions
using correlation and multiple regression are that there is normal distribution, equal
variance (homoscedasticity), data will fit a straight line, and data points are independent
of each other. I used the standard deviation as a measure of spread to test for
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homoscedasticity and a scatter plot to test for linearity. All analysis was done using
SPSS v.21.
Threats to Validity
Internal Validity
The internal validity is the degree to which the study design accurately reflects
whether the change that was measured can be attributed to the program. An important
question of internal validity is whether the observed changes can be attributed to the
intervention and not to other possible causes or alternative explanations (Trochim &
Donnelly, 2008). A randomized experiment is the strongest in of designs in establishing
relationships. Using a randomized control experiment was not feasible for this PBM.
Quasi-experimental design studies do not possess the strength of randomized experiments
for establishing evidence of program effect; however, quasi-experiments can provide
moderate strength of program effect (Austin, 2011). Because of the lack of random
assignment, extraneous confounding variables may negatively influence program effect.
In quasi-experimental design studies, participant characteristics (e.g., age, gender, SES,
industry, etc.) can influence selection bias (Austin, 2011). Propensity scoring allows for
the mimicking of some of the characteristics (reduction or elimination of confounding
effects) of a randomized controlled trial so that the effect of treatment on outcomes can
be estimated directly between intervention and control groups (Austin, 2011).
In the original study by Moore et al. (2013), authors address the potential selfselected control group bias; Moore et al. used propensity score matching to match the
control group to the intervention group. The pilot study focused on the impact on MTM
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on plan-paid health care costs, utilization of medical services, overall day's supply of
targeted medications, and MPRs. The following characteristics were used: age, gender,
baseline day's supply of medications, baseline plan-paid pharmacy costs and medical
costs, physician and inpatient visits, and number of pharmacy-derived chronic disease
states. Individuals for this study were not matched on specific disease states, such as
depression or diabetes (Moore et al., 2013).
External Validity
Medication therapy management was created to be different from all other
counseling program, as fully explained in Chapter 2. More specific, to be eligible,
recipients must have multiple chronic diseases, must be on prescription medication
covered under Medicare Part D drugs, and must be age 65 years and older. External
validity is the extent to which the program can be expected to produce similar effects in
other populations (McKenzie, Neiger, & Thackeray, 2009). The more tailored a program
is to a particular population, the less likely the program can be generalized to other
population and the greater the external validity. The present study focused on the
Medicare eligible recipients who have T2DM only. To improve the validity of the study,
the sample included participants from across the United Sates who were insured with this
large employer prescription benefit plan.
Ethical Procedure Information
This study did not involve experimentation on human participants, and it was
limited to retrospective review of secondary data collected during a previous study done
by Moore et al. (2013). The PBMs analytic department coded each subject's information
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and removed names, Social Security numbers, insurance identification numbers, and
other personal information from the electronic data file. With the approval of Walden’s
IRB, permission to access information, data review, and analysis, a formal Confidential
Information Access Request (CIAR) was filed with the chief privacy officer of the PBM.
All electronic information remains the property of the PBM. No personal information
was used in describing the study and its results.
Summary
In this study, I used a quantitative approach of a secondary data source to examine
the role of MTM pharmacists on medication complexity and adherence. I aimed to
identify the relationship of receiving MTM pharmacist counseling on medication
adherence and complexity in the older adult population. The study follow-up cohort was
limited to participants who had been identified as high-risk members 65 years and older,
had T2DM, and had belonged to a large employer group.
Chapter 3 provided the detailed methodology for this quantitative secondary data
analysis. Using a cohort design, I used multiple regression and correlation to test the
hypotheses that there may be a relationship in receiving MTM pharmacist counseling on
medication adherence and complexity in older adults. Chapter 4 reports the summary of
the results of this quantitative secondary data analysis that either supports or does not
support the research hypothesis presented.
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Chapter 4: Results
Introduction
The purpose of this quantitative study was to examine the relationship of a
pharmacy benefit management (PBM) company’s Medication Therapy Management
(MTM) telephonic pharmacist-consulting program to medication adherence and
medication complexity. It specifically examined this relationship with a group of
Medicare Part D recipients serviced by a single PBM, using a secondary data set from a
previously published study. As described in Chapter 3, multiple regression was used as
the primary statistical analysis.
The results of my study revealed that there was not a statistically significant
relationship between receiving MTM pharmacist support and medication complexity, and
MTM pharmacist support and medication adherence. However, small in magnitude,
there was a statistically significant association between comorbidities and medication
complexity.
This chapter describes the analysis and results conducted to address the study’s
two research questions. The research questions and associated null hypothesis for this
study were:
Research Question 1: Is there an association between receiving medication
therapy management pharmacist telephonic support and medication complexity in
Medicare Part D beneficiaries having T2DM as measured by a change in MRCI scores
after controlling for age, gender, and comorbidities?
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H01: There is not a statistically significant association between receiving
medication therapy management pharmacist telephonic support and medication
complexity in the Medicare Part D beneficiaries with T2DM as measured by a change in
MRCI scores after controlling for age, gender, and comorbidities.
HA1: There is a statistically significant association between receiving medication
therapy management pharmacist telephonic support and medication complexity in the
Medicare Part D beneficiaries with T2DM as measured by a change in MRCI scores after
controlling for age, gender, and comorbidities.
Research Question 2: Is there an association between receiving MTM pharmacist
telephonic support and medication adherence in Medicare Part D beneficiaries having
T2DM as measured by a change in MPR percentages after controlling for MRCI scores?
H02: There is not a statistically significant association receiving medication
therapy management pharmacist telephonic support and medication adherence in the
Medicare Part D beneficiaries with T2DM as measured by a change in MPR percentages
after controlling for MRCI scores.
HA2: There is a statistically significant association between receiving medication
therapy management pharmacist telephonic support and medication adherence in the
Medicare Part D beneficiaries with T2DM as measured by a change in MPR percentages
after controlling for MRCI scores.
Data Collection
This study used secondary archival data exclusively. After receiving approval
from Walden’s IRB (09-26-14-0088140) and obtaining approval through the PBM’s
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Confidential Information Access Request (CIAR) process, I acquired four datasets in
Microsoft Excel format: PCare, GPI drug data, Pre-intervention GPI, and Postintervention GPI. The four Excel datasets were downloaded by me from the PBM’s
secure transport system, converted to an SPSS format, and stored on an external hard
drive.
The datasets contained the following information:
1. The PCare dataset contained the demographic information on the T2DM
study population and the independent variable MPR.
2. The GPI Drug dataset contained the medications that the T2DM
population were receiving or had received during the study period. Each
medication record included the medication dosage form (tablet, ointment,
creams, patches, intravenous and/or subcutaneous route), strength of each
medication and any pertinent special instructions by the manufacturer.
Not all medications have special instructions from manufacturers (see
Appendix A).
3. The Preintervention GPI dataset contained the random ID numbers of the
population, associated medications for each random ID, and days’ supply
of each medication prior to the intervention.
4. The Postintervention GPI dataset contained the same information as the
Preintervention GPI database, but only for the period after the
intervention.
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Creation of New Variables, Total MRCI and Total Medication Count
The GPI Drug data set required the creation of two additional independent
variables., which were labeled TMRCI and TMeds. These variables were created to
explain medication complexity. In creating the TMRCI variable, as one of two of
additional variables to the GPI Drug dataset, I deleted all the records that represented
medications that were in liquid form, intravenous and subcutaneous route, creams, or
ointments. From this modified version, I created a new variable TMRCI. In order to do
this, I first created individual MRCI scores for each drug (Appendix A). Each MRCI
score is the sum of three components (Component A + Component B + Component C).
•

Component A (drug dosage form, tablet, capsule or patch) was weighted
either as 1 or 2.

•

Component B (drug dosing frequency) was weighted from 0.5 to 4
depending upon the manufacturer’s recommended dosing.

•

Component C (special instructions) was weighted from 0 to 3 depending
upon the drug manufacturer’s warnings and precautions. Some
medications had more than one precaution leading to a higher score.

This modified data set was coded as Drug Data with MRCI. The individual
MRCI scores were added to the pre- and postintervention GPI data set and the two new
databases were coded as Preintervention MRCI and as Postintervention MRCI. From
both of these datasets, I then computed a total MRCI (TMRCI) score and total medication
count for each random ID record. The variables TMRCI and total medication count
(TMeds) were created by summing up all the individual MRCI’s and medications for
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each random ID record in the Preintervention MRCI and Postintervention MRCI datasets.
These two new variables were added to the Pcare dataset.
Results
Descriptive Statistics of Participants
The study population consisted of the T2DM subset of a group of high-risk plan
members aged 60 years and older and enrolled at a single PBM Company that provided
data. All source data consisted of a secondary dataset from a previous study conducted by
this PBM Company in 2013 (Moore et al., 2013). The extracted dataset used in the
current study consisted of data that represented 1,158 participants. These data sets were
first scrubbed for missing responses and extreme scores (outliers) that might affect the
results of the statistical analyses. Three records were removed due to missing data
(diabetic MPR change scores). In addition to identify outliers, the raw scores were
converted to z scores where 0 was the mean and the standard deviation was 1. Scores that
were higher or lower than 99% of the other scores (z = 3.29+/-) were considered extreme,
resulting in the removal of the associated records. Six scores met this criterion. After
screening, complete and nonoutlying data were available on 1,148 records (Intervention n
= 543, Control n = 605).
For the T2DM study population, the ages ranged from a minimum of 60 years to a
maximum of 97 years, with a mean age of 75 years and a median of 76 years. There
were 301(49.8%) men and 304 (50.2%) women in the control group, and 258 (47.5 %)
males and 285(52.5%) in the intervention group, which equaled 1,148 participants (Table
3). Table 4 illustrates comorbidity count between groups and genders. There were no
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statistical differences between gender with (p = 0.809). There was a statistical difference
between the groups in comorbidity count of two or less (p = 0.028). The total number of
medications per participant at baseline, ranged from 1–20, with a mean and median of
eight. The differences between the groups were not statistically different (p = 0.33).
Gender differences were not statistically different (p = 0.556).
Table 3
Demographic Characteristics of Study Participants
Gender
Study Group

Males

Females

Total

Control

n = 301

n = 304

n = 605

% within Study Group

49.8 %

50.2%

100%

Intervention

n = 258

n = 285

n = 543

% within Study Group

47.5%

52.5%

100%

Total

n = 589

n = 559

n = 1148

% within Study Group

48.7%

51.3%

100%
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Table 4
Gender and Comorbidity Count Study Group Cross-tabulation
Gender

Study Group

Comorbidities

Male

Female

2 or less Count

70

71

% within Comorbidities

49.6%

Group

Intervention

Total

99

42

141

50.4%

70.2%

29.8%

100%

12.5%

12.1%

16.4%

7.7%

12.3%

489

518

506

501

1007

% within Comorbidities

48.6%

51.4%

50.2%

49.8%

100%

% within Gender

87.5%

87.9%

83.6%

92.3%

87.7%

559

589

605

543

1148

% within Comorbidities

48.7%

51.3%

52.7%

47.3%

100%

% within Gender

100%

100%

100%

100%

100%

3 or more Count

Total

Control

Analysis
Research Question 1: Is there an association between receiving medication
therapy management pharmacist telephonic support and medication complexity in
Medicare Part D beneficiaries having T2DM as measured by a change in MRCI scores
after controlling for age, gender, and comorbidities?
H01: There is not a statistically significant association between receiving
medication therapy management pharmacist telephonic support and medication
complexity in the Medicare Part D beneficiaries with T2DM as measured by a change in
MRCI scores after controlling for age, gender, and comorbidities.
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HA1: There is a statistically significant association between receiving medication
therapy management pharmacist telephonic support and medication complexity in the
Medicare Part D beneficiaries with T2DM as measured by a change in MRCI scores after
controlling for age, gender, and comorbidities.
The means and standard deviations for the MRCI raw scores are shown in Table
5. As observed, there was no statistical difference between the pre and post raw scores
for the two groups. Further, for each participant, a change score was obtained which was
the difference between pre- and postintervention. This difference could show no change
in complexity, a decrease, or an increase in complexity. Here again, the two groups were
not statistically different.
Table 5
Descriptive Statistics for MRCI Raw Scores and Percent’s for Direction of Change
Scores for the Intervention Group (n = 543) and the Control Group (n = 605)
MRCI Complexity
Group

Pre-MRCI

Post-MRCI

M

M

SD

No Change

Decreased

Increased

SD

%

%

%

Intervention

23.03 8.42

22.84

7.98

16.2

41.5

42.3

Control

22.84 9.56

22.56

9.51

12.3

43.3

44.4

As described in Chapter 3, multiple regression was employed to examine the
association between the MTM program and medication complexity after controlling for
age, gender, and comorbidities. The descriptive statistics for these variables are provided
in Table 6. For purposes of the regression analysis, the MRCI change score was
designated as the dependent variable. Comorbidities, age, and gender were the
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independent variables and considered as covariates in the regression analysis. The
differences between the mean change scores for the two groups as well as the covariates
for the two groups were small and similar to Table 5. The change scores ranged from -24
to 36. Minus or negative scores reflected greater complexity on the post MRCI while
positive change reflected less complexity. As such, the means for MRCI change indicate
that, on average, both groups showed slightly less complexity on the MRCI postintervention while their standard deviations indicate that there was wide variability within
each group. Observation of the covariates also indicates that the groups were quite
similar.
Table 6
Descriptive Statistics for MRCI Change and Covariates for the Intervention Group (n =
543) and Control Group (n = 605)
MRCI change

Covariates
Comorbidities

Group

M

Age

Male

Female

SD
M

SD

M

SD

n

%

n

%

Intervention 0.28

6.94

3.37

0.74

74.6 8.14 258 47.5 285 52.5

Control

6.36

3.25

0.82

75.7 8.08 301 49.8 304 50.2

0.20

Table 7 further describes the variables through their bivariate correlations with
each other. Correlation and regression require the measures on each participant to be
numerical. To meet this requirement group membership was coded as 0 (control group)
and 1 (intervention group). Likewise, gender was coded as 0 (male) and 1(female).
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Row 1 of the matrix is of most interest and informative. It shows that the
dependent variable (MRCI Change) had near zero correlation with the primary
independent variable of group (r = 0.01). Reading further across the row indicates zero
and near zero correlations between MRCI Change for age and gender. While the
correlation with comorbidities was statistically significant it was small in magnitude (r =
0.10, p < 0.05). The correlations thus support the previous descriptive statistics in Tables
5 and 6, which suggest that the association between group membership and MRCI
Change would be small.
Table 7
Intercorrelations between MRCI Change, Group, and Covariates
Variable
MRCI Change
Group

MRCI Change

Group

Age

Gender

Comorbidities

__

0.01

0.00

-0.02

0.10**

__

-0.07**

0.02

0.08**

__

-0.01

-0.06*

__

0.10**

Covariates
Age
Gender
Comorbidities

__

*p < 0.05, **p < 0.01.

Based on the descriptive statistics and correlations provided above, the
expectation was that the regression analysis would not reveal additional information
about the association between group membership and MRCI Change. However, it was
felt that it would be useful to include it as part of this analysis. Hierarchical multiple
regression was the procedure employed. In this approach, the variables were entered in
steps where the primary independent variable is entered as the first step followed by the
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variables that are considered as covariates. As part of the procedure, the data were first
examined for the assumptions underlying regression and no violations were found.
Assumptions using correlation and linear regression are that there is normal distribution,
equal variance (homoscedasticity), data will fit a straight line, and data points are
independent of each other (McDonald, 2009). The 0.05 level of probability was used as
the criterion for statistical significance.
Provided in the table are the standardized beta weights (β), the t-ratios, statistical
probabilities (p), the multiple correlation (R). Whereas Table 7 provides the bivariate
correlation (r) between each set of two variables, multiple correlation is the correlation
when variables are combined together. Of interest in hierarchical regression is the
change in the multiple correlation (R) as the variables are combined as the analysis
proceeds from step-to-step.
For these data, there were four steps. The first step was the primary independent
variable (group) and its association with the dependent variable, medication complexity
(MRCI Change). Because it is the first step and just two variables (MRCI Change and
Group), the multiple correlation (R = 0.01) is the same as the bivariate correlation in
Table 7 (r = 0.01). Age was entered as Step 2 and contributed no change to R. This
coincides with Table 7, which shows that there was no correlation between age and
MRCI Change (r = 0.00). When gender is added in Step 3, the multiple correlation
increased slightly (R = 0.02) since it is the combined relationship between MRCI, group,
age, and gender. Comorbidities were entered as the final step and the multiple correlation
increased from 0.02 to 0.10. The t and p columns indicated the statistical significance of
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R. To be statistically significant p had to be 0.05 or less. The p value for t = 3.44 was
0.01 thus showing statistically significance beyond the 0.05 criterion.
The standardized beta weight (β) is useful in that from a prediction perspective
the weights may be compared directly. Observation of the weights indicates that
comorbidities would contribute nearly 10 times more weight in predicting medication
complexity (MRCI Change) than any of the other variables.
In summary, for research question 1, no support was found for an association
between MTM telephonic support and medication complexity as measured by a change in
MRCI scores. Thus, the null hypothesis (H01) was not rejected. The only association
found was between comorbidities and medication complexity as measured by change in
MRCI scores. While the relationship was statistically significant, it was small in
magnitude.
Table 8
Hierarchical Regression Analysis Summary for Group and Covariates Predicting MRCI
Change
________________________________________________________________________
Step and Variable
β
t
p
R
________________________________________________________________________
Step 1
Group
0.01
0 .20
0.84
0.01
Covariates
Step 2
Age
0.00
0.11
0.92
0.00
Step 3
Gender
-0.02
-0.50
0.62
0.02
Step 4
Comorbidities
0.10
3.44
0.01
0.10
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Research Question 2: Is there an association between receiving medication
therapy management pharmacist telephonic support and medication adherence in
Medicare Part D beneficiaries having T2DM as measured by a change in MPR
percentages after controlling for MRCI scores?
H02: There is not a statistically significant association between receiving
medication therapy management pharmacist telephonic support and medication
adherence in the Medicare Part D beneficiaries with T2DM as measured by a change in
MPR percentages after controlling for MRCI scores.
HA2: There is a statistically significant association between receiving medication
therapy management pharmacist telephonic support and medication adherence in the
Medicare Part D beneficiaries with T2DM as measured by a change in MPR percentages
after controlling for MRCI scores.
The means and standard deviations for the variables used for this research
question are shown in Table 9. The pre and postintervention means and standard
deviations indicate small differences between the two groups for MPR. The Percent
Change values indicate that there was some difference between the means with much
greater variation within the intervention group as shown by the standard deviations. The
MRCI means and standard deviations are the same as those in the previous research
question. They are shown again here because the MRCI is used as the covariate.
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Table 9
Descriptive Statistics for Pre and Post-MPR, MPR Percent Chang, and the MRCI
Covariate for the Intervention Group (n = 543) and Control Group (n = 605)
_______________________________________________________________________
Pre-MPR

Post-MPR

% Change

Pre-MRCI

Group
M
SD
M
SD
M
SD
M
SD
________________________________________________________________________
Intervention
.77 * .25
.78* .27
.64
8.95
23.03 8.42
Control
.74* .25
.73* .29
.22
1.93
22.84 9.56
_______________________________________________________________________
* Multiply ratio by 100 to equal percentage. 80% is considered adherent.

The correlations observed in Table 10 indicate small relationships between the
three variables with the correlation between the medication adherence (MPR percent
change) and group being near zero (r = 0.03). Although the correlation between
medication complexity (Pre-MRCI) and medication adherence (MPR Percent Change) is
statistically significant, it is small in size.
Table 10
Intercorrelations between MPR Percent Change, Group, and Covariate
_____________________________________________________________________
Variable

MPR % Change

Group

Pre-MRCI

____________________________________________________________________
MPR Percent Change
__
0.03
0.05*
Group

__

0.01

Covariate
Pre-MRCI
__
______________________________________________________________________
*p < 0.05.
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Hierarchical regression was also used to examine research question 2. The results
shown in Table 11 indicate no statistical support for an association between the MTM
pharmacist telephonic support program and medication adherence as represented by the
percentage change scores.
Table 11
Hierarchical Regression Analysis Summary for Group and Covariate Predicting MPR
Percentage Change
______________________________________________________________________
Step and Variable
β
t
p
R
________________________________________________________________________
Step 1
Group
0.03
1.11
0.27
0.03
Covariates
Step 2
0.05
1.82
0.07
0.06
______________________________________________________________________

Summary
The study examined an MTM pharmacist telephonic consulting program and its
relationship to medication complexity and adherence to medications. Regression
analyses on post program complexity and adherence change scores showed no correlation
between MTM telephonic pharmacist support and the reduction in complexity or an
increase in adherence. However, regression analysis did show that comorbidities were
influential in predicting medication complexity (MRCI Change) than any of the other
variables.
In Chapter 5, I discuss the results presented in this chapter and interpret them in
light of current theory and literature. I present the importance of these finding to this
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population, and MTM pharmacists and propose further research to validate these results
and explore using MRCI score as a tool in greater depth as well recommend PBM MTM
interventions to reduce medication complexity and increase medication adherence in the
older adult with T2DM.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The purpose of this quantitative study was to examine the relationship of a
pharmacy benefit management (PBM) company’s Medication Therapy Management
(MTM) telephonic pharmacist-consulting program to medication adherence and
medication complexity. It specifically examined this relationship with a group of
Medicare Part D recipients serviced by a single PBM, using a secondary data set from a
previously published study. The study controlled for age, gender, and comorbidities, and
was designed to answer two primary research questions:
1) Is there an association between receiving medication therapy management
pharmacist telephonic support and medication complexity in Medicare -D
beneficiaries having T2DM as measured by a change in MRCI scores after
controlling for age, gender, and comorbidities?
2) Is there an association between receiving medication therapy management
pharmacist telephonic support and medication adherence in Medicare -D
beneficiaries having T2DM as measured by a change in MPR percentages
after controlling for MRCI scores?
This retrospective study used quantitative archival data from a PBM located in the
Midwest region of the United States. Regression analysis tested whether there were
changes in postprogram complexity and adherence by the MTM’s pharmacist telephonic
support; the overall findings showed no statistical correlation between MTM telephonic
pharmacist support and the reduction in complexity or an increase in adherence.
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However, regression analysis did show that after controlling for the covariates
comorbidities, age, and gender, comorbidities significantly (p=0.01) predicted medication
regimen complexity than age or gender. These findings suggested that in complex
disease states such as Type 2 Diabetes Mellitus (T2DM), there is no statistical correlation
between MTM pharmacist telephonic support and medication adherence.
Interpretation of the Findings
Type 2 Diabetes Mellitus is often considered a complex disease and is the
seventh-leading cause of death and morbidity in the United States (ADA, 2013; Qaseem
et al., 2012). Type 2 Diabetes Mellitus is the most common form of diabetes and its
prevalence increases with age; at the time of the study, nearly 25% of the United States
population older than 65 years had T2DM (Qaseem et al., 2012). If left untreated or
poorly treated, the disease leads to microvascular (retinopathy, nephropathy, and
neuropathy), and/or macrovascular (coronary artery disease, heart failure,
cerebrovascular and peripheral vascular disease) complications (ADA, 2013; Qaseem et
al., 2012).
Adherence is a key link in obtaining positive outcomes for medical care.
Medication Possession Ratio percentages (ratios) in this study were used to represent
medication adherence. This study used stages of change (SOC) theory as its theoretical
foundation, which describes the stages of readiness, the decisional balances, and selfefficacy used by individuals in making a behavior change. These changes usually occur
in stages, and are not always linear (Prochaska & DiClemente, 1983). Pharmacists are
important in assisting patients with needed behavioral and medication regimen changes to
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maintain adherence to pharmacological treatment for improving the prognosis of T2DM
(Rodriguez de Bittner & Zaghab, 2011; Viswanathan, 2012).
The study results showed that there was neither increase nor statistical decrease in
medication adherence in the T2DM population. The treatment guidelines for treating
T2DM are annually updated to promote better management of this population, and as
such, treatment may becomes more complicated. T2DM treatment not only includes the
medication for the disease itself, but also includes medications for preventative use for
downstream complications and medications for the associated comorbidities that may be
present (ADA, 2013). Many consultations with the patients and pharmacists end with
new medications added to patients’ already complex regimens due to the standard
treatment guidelines for T2DM. For successful MTM consultations, pharmacists need to
use combinations of skills that will assist patients with taking their medication and any
new life-style changes into a patient’s life. Adherence to prescribed medication is crucial
to therapeutic success.
MTM Pharmacist Telephonic Support and Medication Complexity
Research Question 1: Is there an association between receiving medication
therapy management pharmacist telephonic support and medication complexity in
Medicare Part D beneficiaries having T2DM as measured by a change in MRCI scores
after controlling for age, gender, and comorbidities?
Quantifying regimen complexity is a concept that was introduced in 2004 by
George et al. (2004). Medication complexity is more than the amount of tablets that a
patient takes; it is the summation of dosage forms, frequency of dosing, and additional
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usage instructions and varies from one medication to another (George et al., 2004, Libby
et al., 2013). For example, Choudhry et al. (2011) showed that patients’ making multiple
pharmacy trips is a significant factor in therapeutic complexity. Medication complexity
is strongly correlated with medication nonadherence (Choudhry et al., 2011; Corsonello
et al., 2009; Libbey et al., 2013; Moore, Shartle, Faudskar, Matlin, & Brennan, 2013;
Pollack et al., 2010). MRCI scores in this study represented medication complexity.
This research study used a standard protocol of evaluating patients medication
regimens (see MTM services in Chapter 2); the results showed that there was no
association between receiving MTM pharmacist telephonic support on reducing
medication complexity (p= 0.84). The patient’s medication regimens were not, however,
simplified as a result of the MTM pharmacist consultation. This finding is consistent
with other studies (George et al., 2004; Libby et al., 2013; Mansur et al., 2012) that found
that it is very difficult for the pharmacist to quantify regimen complexity without using a
reliable tool such as the MRCI index. When comparing two medication regimens with
the same medication counts side by side, both regimens may look very similar, when in
fact, they are not (Libby et al., 2013). The common practice of using a simple medication
count ignores medication regimen complexity. This was evident in this study and its
conclusion that complexity was not reduced as a result of the consultation by the
pharmacist.
Comorbidities and Complexity
When controlling for covariates (age, gender, and comorbidities), age and gender
were not statistically correlated (r=0.00, p=0.92; and r=0.02, p=0.62, respectively) with
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medication complexity. This finding is consistent with other studies (Corsonello et al.,
2009; Mansur, Weiss, & Beloosesky, 2012). However, in the current study, results found
that comorbidities were statistically correlated with medication complexity (r=0.10,
p=0.01), although the strength of this correlation was weak. This finding adds to the
earlier findings by Libby et al. (2011) that disease states such as T2DM, Geriatric
Depression, and HIV are more complex in treatment. More than 45% of patients in the
three cohort disease states in the present study were on more than 11 different
medications, compared to 28% in the hypertension cohort. This group’s mean MRCI
scores ranged from 23–26, versus 18 in the hypertension cohort. Medications that were
prescribed outside of the cohort-defining disease medications also contributed the most to
the MRCI patient scores. The complexity of treating T2DM is that the treatment consists
of the medications for the disease itself, plus treatment medications for the comorbidities
that present due to the complications of the disease (ADA, 2012; Qaseem et al., 2012).
These treatment regimens are often complex, intrusive, and inconvenient for the patient
often-influencing medication adherence, as noted by Qaseem et al. (2012).
Intensive diabetes control includes using medications to control the diabetes itself,
but also preventative medications to prevent diabetes-related complications (ADA, 2013).
Nonadherence affects not only a patient’s T2DM itself, but also any diabetes-related
complications such as hypertension, heart disease, and kidney disease that they may also
have (ADA, 2013). Treatment of diabetes thus presents clinical challenges to MTM
pharmacists related to polypharmacy, prevalent symptoms, and complexity of care.
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MTM Pharmacist Telephonic Support and Medication Adherence
Research Question 2: Is there an association between receiving medication
therapy management pharmacist telephonic support and medication adherence in
Medicare Part D beneficiaries having T2DM as measured by a change in MPR
percentages after controlling for MRCI scores?
Medication adherence has been defined as the degree to which patients take their
medications that have been prescribed to them by their health care providers (Osterberg
& Blaschke, 2005). Adherence can vary across the different chronic illnesses, from
minimal to very significant (Ingersoll & Cohen, 2008). Adherence was significant with
less complex disease conditions such as hypertension or dyslipidemia as compared to
more complex disease conditions such as T2DM, Geriatric depression or Asthma (Moore
et al., 2013). Consequences of nonadherence or limited adherence to T2DM medical
regimens may result in lack of glycemic control, with downstream increases seen in
increased associated medical costs (Moore et al., 2013; Pollack, Chastek, Williams, &
Moran, 2010).
There are two preferred methods used for measuring medications adherence,
Medication Possession Ratio (MPR) and Proportion of Days Covered (PDC). For this
study, I focused on the MPR. The MPR is a ratio that reflects the proportion of days
during a defined period that a patient had possession of any of the drugs used to treat an
illness (Choudhry et al., 2009; Karve et al., 2008; Karve et al., 2009; Nau, 2012).
When using MPR, the ratios are always between 0 and 1 and may be represented
by a percentage (ratio multiplied by 100) and a ratio of ≥ 0.80 (80%) is the industry
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standard acceptance for adherence (Osterberg & Blaschke, 2005). The reported
adherence rate reflects the percent of patients who achieved a high level of adherence to
the target class of drugs. Adherence to a complex disease such as T2DM is difficult for
older adults as the medication regimen is complex.
In my study, the base adherence (pre-treatment) mean ratios for the T2DM
intervention group were 0.77 (77%), and T2DM control group were 0.74 (74%). The
post-treatment mean ratio of the T2DM intervention group was 0.78 (78%) and control
was 0.73 (73%). Results of my study showed that both the intervention and control
group remained below the industry standard of acceptable adherence rate of 0.80 or 80%
(Osterberg & Blaschke, 2005). Medication Therapy Management pharmacists may have
improved patient outcomes in other arenas in patient care (problem solving, medication
costs, etc.). However, patients remained vulnerable to possible adverse events of being
non-adherent leading to increased risks for all cause hospitalization and mortality (Ho et
al., 2006; Lau & Nau, 2004; Yang, 2009). Insurers, self-insured employers, and
government agencies primarily will shoulder the increased medical costs and medications
(Shrank, Porter, Jain, & Choudhry, 2009). The low adherence rates of the T2DM cohort
in my study are consistent with existing literature representing complexity with this
chronic disease (Choudhry et al., 2011; Corsonello et al., 2009; Pollack, Chastek,
Williams, & Moran, 2010). The under recognition of medication nonadherence in older
adults with T2DM can have adverse consequences and it is important that MTM
pharmacists strive to improve adherence.
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My study results found there was no significant difference between receiving
MTM pharmacist counseling and medication adherence (p=0.36) even after controlling
for medication complexity (p=0.07). This finding correlates with other studies that have
compared regimen complexity with medication adherence (Moore et al., 2013; Pollack,
Chastek, Williams & Moran, 2010). However, study results did identify a significant
difference between medication adherence and medication complexity (p=0.034). Results
of this study showed that with older adults T2DM, complex medication regimens
influenced medication adherence. This result is important to PBM’s and MTM
pharmacists, when evaluating medication regimens. Complexity is an important factor to
consider when trying to increase medication adherence. Multiple day dosing, complex
instructions and multiple trips to the pharmacy have been implicated for the failure of
completion of first fill or refills of prescriptions (Choudhry et al., 2011; Karter, et al.,
2009; Ho et al., 2006). This study results highlight an essential aspect of the therapeutic
cascade that may be burdensome to the patient. These results add to current literature in
support of the importance of considering medication complexity on medication adherence
especially in the T2DM population (Choudhry et al., 2011; Corsonello et al., 2009;
Ingersoll & Cohen, 2008; Mansur, Weiss, & Beloosesky, 2012; Nam et al., 2011).
Current literature supports patient factors such as depressed economic status, and
cognitive/physical impairment, are difficult modifiable correlates of nonadherence
(Corsonello et al., 2009; Ingersoll & Cohen, 2008; Mansur, Weiss, & Beloosesky, 2012;
Nam et al., 2011). However, polypharmacy, reducing adverse drug events and regimen
complexity are to some extent modifiable correlate of the outcome (Choudhry et al.,
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2011; Corsonello et al., 2009; Ingersoll & Cohen, 2008; Mansur, Weiss, & Beloosesky,
2012; Nam et al., 2011). Despite the numerous studies that exist around medication
nonadherence, some grey areas still exist in the understanding of all the factors involved
in nonadherence in older adults. Medication Therapy Management pharmacists have the
opportunity to work collectively with the physician and patient to offer solutions that will
help increase medication adherence in this complex patient population.
Limitations of the Study
There were several limitations to this study:
•

I used archival data from a previous study of health care in a large PBM.
The selection, quality, included variables, and the method of data
collection were not under my control and validation was not possible.

•

Since the MRCI index score was used retrospectively and not
prospectively, the MTM pharmacists did not use this tool when evaluating
patient profiles for medication complexity. This may have influenced
outcomes regarding reducing medication complexity and increasing
medication adherence.

•

Only records of oral maintenance medications pertinent to the disease
itself, or to existing comorbidities, and preventive maintenance
medications were considered for my study. I did not consider the use of
other medications such as anti anxiety, sleep aids, and or as needed pain
medications. Libby et al. (2013) tracked all the over the counter
medications (OTCs) taken by the patients in this study. The addition of
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OTCs, added another 12% to the total MRCI scores in the Diabetes
Mellitus patient cohot.
Recommendations
This study represents a first step towards filling the information gap on research
involving PBM MTM pharmacists in telephonic consulting roles on medication
complexity and nonadherence. Although no statistically significant results were
identified between the independent variable MTM pharmacist counseling program and
the dependant variables medication adherence (MPR) and medication complexity
(MRCI), a causational link between comorbidities and medication complexity could not
be ruled out.
The results from research questions 1 and 2 contribute to existing knowledge of
comorbidities adding to disease state complexity, and medication complexity, and their
effects on medication adherence. Based on these results, it is important that PBM MTM
pharmacists consider medication complexity and using a validated tool such as the MRCI
index when evaluating complex medication regimens to increase medication adherence.
Further studies are needed to evaluate the use of the MRCI index prospectively by PBM
MTM pharmacists on medication adherence and medication complexity.
Implications
Implications for Social Change
The number of medications taken by older adult’s increases with age and diseaserelated comorbidities carry a high risk of polypharmacy (Budnitz, Lovegrove, Shehab, &
Richards, 2011; Corsenello, Pedone, Corica, & Incalzi; Mansur, Weiss, & Beloosesky,

107
2012). Polypharmacy among older adults with T2DM has been associated with poor
adherence, increased risk of adverse events, leading to hospitalizations, emergency
department visits, and all cause mortality (Chisholm-Burns et al., 2010; Congressional
Budget, 2010; Doggrell, 2010; Moore et al., 2013; Roebuck et al., 2011; Yang et al.,
2009). Medication complexity and nonadherence have negative effects on medication
adherence and therepeutic outcomes which could undermine effective treatments in
complex chronic diseases such as T2DM (Choudhry et al., 2011; Libby et al., 2013;
Pollack, Chastek, Williams, & Moran, 2010).
Pharmacy Benefit Management MTM telephonic programs provide a unique
opportunity to promote health by assisting patients to receive the appropriate medication
and to adhere to their medication regimens. The MRCI index is a proven method of
identifying medication complexity and would provide PBM MTM pharmacists a more
efficient approach to identifying high-risk patients. This would allow for targeted
interventions to improve adherence and achieve optimum outcomes in diabetes
management, potentially reducing morbidity and mortality. Using medication
complexity as an indicator to identify medication nonadherence may be a useful strategy
for PBMs to reduce long-term costs and decrease downstream costs to insurance
companies and patients (Congressional Budget, 2010; Lawrence et al., 2012; Shrank,
Porter, Jain, & Choudhry, 2009).
Implications for Stages of Theory Change
This study strengthens the overall concept of the theory, as it relates to patient
behavior. To improve medication adherence, the causes of nonadherence must be
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understood followed by different strategies by pharmacists in consulting patients on their
medications. As the individual builds self-efficacy, the individual's decisional balance
has a positive shift forward propelling the individual to the next stage (Prochaska et al.,
2008). Increasing self-efficacy is important to maintaining a new behavior, such as being
medication adherent. Pharmacists are instrumental in factors influencing adherence,
including patient’s comprehension of medication regimen and its benefits, potential side
effects, and costs (Moczygemba, Barner, Gabrillo, & Godley, 2008; Moore et al., 2013;
Patwardhan, Duncan, Murphy, & Pegus, 2012; Rodriguez de Bittner & Zaghab, 2011;
Schnipper et al., 2006 ).
Recommendations for Practice
The results of my study, while not confirming statistically significance, suggest
that there may be some merit in pursuing the use of the MRCI index as a valid tool for
evaluating medication complexity as a means to increase medication adherence. The lack
of statistical significance should not be interpreted to mean that MTM pharmacists were
not effective in increasing medication adherence. This study showed that it was not
demonstrable in this study. As was pointed out in Chapter 2, it is important to evaluate
all the factors that influence medication nonadherence, including medication complexity
(Ingersoll & Cohen, 2008; Libby et al., 2013; Mansur, Weiss, & Beloosesky, 2012;
Pollack et al., 2010). When evaluating medication complexity, it is important to use a
validated tool such as the MRCI index rather that medication count (George et al., 2004).
These results should be presented to PBMs in hopes the it will spawn additional inquiry
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into using the MRCI index as a tool to assist MTM pharmacists when evaluating
medication profiles for medication complexity.
Conclusion
For older adults, treatment of T2DM will require continuous medical care and
patient self-management including using preventative strategies beyond glycemic control
(ADA, 2013). Preventive strategies include cardiovascular disease risk management.
Type 2 Diabetes Mellitus has been shown to be major risk factor for cardiovascular
disease, increasing the risk for morbidity and mortality for these individuals (ADA,
2013). Treatment strategies include high blood pressure management, dyslipidemia/ lipid
management and coronary heart disease prevention (ADA, 2013). The care of older
adults with T2DM is complicated by their comorbidities and poly pharmacy. Pharmacists
are integral in the ongoing patient self-management education. Pharmacists’ support is
critical to preventing acute and long-term complications.
Baseline data from this study indicate that the T2DM cohort were not medication
adherent and are vulnerable to possible long-term complications. Pharmacy benefit
managers and MTM pharmacists must consider not only the complications of the
nonadherence to the individual but the increased downstream costs to the insurers, selfinsured employers, and government agencies. There are many factors that influence
medication nonadherence, medication complexity is a modifiable factor in medication
nonadherence.
Healthcare plans and providers continue looking into ways to measure quality
care that is being provided by healthcare delivery. Healthcare plans are now
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incorporating measures of quality in an effort to evalute themselves, how employers
choose plans and consumers decide who provides their care (Seabury, Lakdawalla,
Dougherty, Sullivan & Goldman, 2015). Medication adherence is an excellent entrant for
quality measurement, for as medication adherence increases, regimen complexity and
medical costs decrease, and clinical outcomes increase (Cutler & Everett, 2010; Seabury,
Lakdawalla, Dougherty, Sullivan & Goldman, 2015; Viswanathan et al., 2012).
Concerted efforts need to be made to increase awareness to PBM’s and MTM
pharmacists involved with evaluating medication profiles the importance for evaluating
medication complexity especially in complicated disease states such as T2DM. More
prospective studies are needed using the MRCI index as a means to evaluate regimen
complexity. Exploring this using a mixed study approach would be valuable for getting
phamacists’ perceptions about the use of the MRCI index when evaluating patient
profiles.
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Appendix A: Medication Regimen Complexity Index Section
Dosage forms (A)

Oral

Topical

Ear, Eye & Nose

Inhalation

Others

Weighting

Dosing Frequency (B)

Weighting

Capsules/Tablets
Gargles/Mouthwashes
Gums/Lozenges
Liquids
Powders/ Granules
Sublingual sprays/ tabs
Creams/ Gels/Ointments

1
2
2
2
2
2
2

Once daily
Once daily as needed (prn)
Twice daily
Twice daily prn
Three times daily
Three times daily prn
Four times daily

1
0.5
2
1
3
1.5
4

Dressings
Patches
Sprays

3
2

Four times daily prn
Every 12 hrs
Every 12 hrs prn

2
2.5
1.5

Ear drops/ creams/
ointments
Eye drops/gels/ointments
Nasal drops/ cream/ointment
Nasal spray
Accuhalers
Metered dose inhalers
Nebulizer
Dry powder inhaler
Enemas
Injections:

Prefilled
Vials
Suppositories/ Vaginal
creams

1
3
3
3
3
3
4
5
3

Every 8 hrs
Every 8 hrs prn
Every 6 hrs
Every 6 hrs prn

2
4.5
2.5

Every 4 hrs
Every 4 hrs prn
Every 2 hrs
Every 2 hrs prn

6.5
3.5
12.5
6.5

2
3
4

On alternate days or less
frequently

2

2
Additional Directions (C)
Break/ crush/ dissolve
Multiple units at one time
(e.g. 2 tablets, 2
inhalations)
Variable dose (e.g. 1 to 2
tablets, 2 or 3 inhalations
Take at specific time/s
(e.g. at bedtime, at noon)
Relation to food (e.g.
before or after meals, with
a snack)
Take as directed
Tapering/increasing dose
or alternating dose (1
tablet in the morning and 2
tablets at bedtime)

Note. Adapted from George et al., 2004.

3.5

Weighting
1
1
1
1
1
2
2
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Appendix B: Confidential Information Access Request
From: Kemper, DiAnne M.
To: Swift, Katherine
Subject: FW: CIAR# 4149665 Status Update - Request Approved
Date: Wednesday, January 07, 2015 2:18:48 PM
DiAnne Kemper | CVS Caremark | Advisor, Information Governance & Privacy, Legal | 480-391-4649 |
480-314-6905 | 9501 E Shea
Blvd, MC016, Scottsdale, AZ 85260 | dianne.kemper@cvscaremark.com
CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for
the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received
this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If
you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this
communication and any attachments.

From: Information.Governance@CVSCaremark.com
[mailto:Information.Governance@CVSCaremark.com]
Sent: Tuesday, November 04, 2014 3:33 PM
To: Kemper, Dianne M.
Subject: CIAR# 4149665 Status Update - Request Approved
Information Governance and Privacy Operations
CIAR Team
A Confidential Information Access Request (CIAR) has been reviewed by the CIAR
Team.
CIAR Record: 4149665
Project Name: Dissertation: Analysis of telephonic pharmacist counseling
This CIAR is now APPROVED.
Click on the hyperlink provided above to access the CIAR record.
Please contact Information.Governance@CVSCaremark.com if you have any
questions.
This notification has been sent to:
Submitter
Requestor
CC: Analytics Approver
Information Asset Steward / Custodian
You are receiving this email because of your assigned responsibility within the CIAR
record. This is a system generated email.
eGRCNOTCIAR10.

